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The ability of conducting polymers such as poly(3,4-ethylenedioxythiophene) (PEDOT) to store 
a drug as a dopant and release it following electrical stimulus make them an intriguing coating 
possibility for intracortical electrodes, along with their ability to reduce electrode impedance. 
The mechanism allows for the release of an assortment of useful agents, including anti-
inflammatory drugs and neuromodulatory chemicals. We evaluated the release capabilities of a 
multi-walled carbon nanotube (MWCNT)-doped PEDOT coating incorporating the anti-
inflammatory steroid dexamethasone in vitro using sputtered-gold macroelectrodes, and then 
applied the coating to half of the electrodes within 16-shank platinum/iridium floating 
microelectrode arrays for chronic in vivo evaluation in rat visual cortex. Impedance 
measurement, neurophysiological recording, and cyclic voltammetric release stimulus (-0.9 V to 
0.6 V, 1 V/s, 20 cycles) was performed daily to all channels. On the 11th day, histology was 
performed to quantitatively characterize inflammatory tissue response using OX42 (microglia) 
and GFAP (astroglia). Equivalent circuit analysis was performed to assist the interpretation of 
impedance data. Our results indicated that the MWCNT/PEDOT-coated gold macroelectrodes 
released double the amount of dexamethasone using passive release followed by CV stimulation 
(10 sets of 20 cycles) compared to passive release alone. Coatings applied to Pt/Ir 
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microelectrodes reduced 1 kHz impedance in PBS by approximately 38%. Coated probes in vivo 
exhibited a significant decrease in 1 kHz impedance for the initial three days of implantation 
followed by an increase, between days 4 and 7, to values equivalent to those exhibited by 
uncoated probes. Neurophysiological recording performance of coated and uncoated probes 
remained equivalent for the duration of the experiment, in terms of signal-to-noise ratio and 
noise amplitude.  Histology revealed no significant difference in tissue inflammatory response to 
coated and uncoated electrodes. Explant imaging revealed the presence of a membranous film 
enveloping coated electrodes, and equivalent circuit analysis suggested that the day 4-7 increase 
in 1 kHz impedance of coated electrodes was due to a decrease in effective surface area of the 
coatings as well as the core electrodes. Additional work was also performed developing a model 
for the in vivo microinjection of the enzyme Chondroitinase ABC into tissue surrounding 
implanted microelectrodes. 
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1.0   INTRODUCTION 
 
 
 
Cortical neural prostheses (CNPs) are devices which interface directly with the neocortex of the 
central nervous system in such a way that signal in the form of neural activity may be recorded 
and interpreted by a computerized algorithm. These devices function through the implantation of 
penetrating microelectrodes into cortical tissue, providing them with the ability to detect the 
activity of individual neurons1. Such technology holds enormous scientific and clinical potential 
as it allows for a degree of interaction with fundamental cognitive mechanisms in vivo that is 
unmatched by other recording or imaging methods. A particularly successful application of 
CNPs has been in the development of thought-controlled assistive devices, which extract motor 
intent information from the cortex and translate this intent into commands1–6. However, the 
applicability of cortical neural prosthetics within clinical devices is limited by their current 
effective post-implantation lifetime, defined by a combination of neuron death7–9, progressive 
performance degradation5,10–13, and device malfunction or breakage14,15. While select studies 
have yielded adequate recording performance for well over a year after implantation16–20, on 
average these devices perform unreliably in the long term5,21, limiting their translation to clinical 
and commercial devices where performance would be expected to persist over decades. The 
studies summarized in this dissertation demonstrate the use of recently-developed techniques to 
better understand the physiological factors of cortical neural prosthesis failure and promote the 
development of novel strategies to improve the reliability of these devices in clinical use. 
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1.1   NEURAL PROSTHETICS 
Cortical neural prostheses are a component of a larger category of implants known as neural 
prosthetics, which include both recording and stimulating devices intended to interact with a 
wide variety of neural targets with the purpose of substituting sensory, motor, or cognitive 
modality that has been damaged due to disease or injury1. At this time, the neural prostheses that 
have shown the most clinical and commercial success have been those that provide electrical 
stimulation to target tissue, such as deep brain stimulation (DBS) for the treatment of 
Parkinson’s disease22, or the stimulation of cochlear neurons to partially restore lost hearing23. In 
addition to Parkinson’s disease, DBS has seen successful application in the treatment of a wide 
variety of pathologies, including chronic pain, epilepsy, dystonia, and essential tremor, with over 
80,000 device recipients since 1997 according to Medtronic, Inc24.  Cochlear implants have seen 
even more widespread adoption, with 219,000 recipients worldwide as of 2010 according to the 
National Institute of Health25. A more recently developed neural prosthetic is the retinal implant, 
which is typically inserted against the inner surface of the retina and provides controlled 
stimulation to ganglion cells using a flat multi-electrode array. These devices have seen 
extensive successful clinical testing, with the first commercial example, the ARGUS II (Second 
Sight Medical Products, Inc.), being approved by the US FDA for sale in February 2013. 
Neural prosthetics intended to record cortical activity come in a variety of embodiments 
that each feature differing degrees of size, resolution, and surgical invasiveness. The least 
invasive are those prostheses which employ electroencephalography (EEG), or a network of 
large electrodes applied directly to the scalp surface that record cortical activity through the skin 
and skull (Fig. 1.1a). While these devices do not typically possess anywhere near the spatial or 
temporal resolution of more invasive approaches, their safety and ease of use make them an 
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attractive option for some applications, such as systems that allow patients to communicate by 
mentally spelling words on a screen26 or controlling a cursor in 2D or 3D space27–30. 
Electrocorticography (ECoG) is a significantly more invasive technique that involves the chronic 
implantation of a flexible array of electrodes under the skull and above the brain surface (Fig. 
1.1b). ECoG techniques have been developed allowing patients to spell words on a screen31,32 
and voluntarily control seizures31, and may be used to decode upper limb movements33. 
 The focus of this dissertation is on penetrating microelectrodes (Fig. 1.1c), which while 
being the most surgically invasive of the chronic interface varieties also possess the greatest 
spatial and temporal resolution, being capable of recording and characterizing the activity of 
individual neurons within cortex or spinal cord1,5,16,34. Perhaps the most prominent clinical goal 
of such devices is the development of motor control systems for limb prostheses or 
communication interfaces3–6,35, through the decoding of recorded cortical activity into 
representations of desired movement. Such technology has the potential to benefit individuals 
suffering from movement or communication deficits caused by spinal trauma-induced paralysis 
(over 1.2m in the US in 200936) and a variety of conditions including stroke, cerebral palsy, 
amyotrophic lateral sclerosis, multiple sclerosis, and limb amputation1–3,5,6. However, for such a 
device to be considered acceptable for clinical use, it must retain the ability to reliably and 
reproducibly record large populations of neurons for several decades, and ideally the duration of 
a human lifetime3,12,17,21. Existing CNPs are incapable of providing this level of reliability, with 
unacceptable degrees of variability in yield of recorded neurons being observed between subjects 
and individual electrodes5,10,11,13,37–39. This chronic variability in recording performance is 
thought to be in a large part due to the tissue inflammatory response that inevitably occurs 
around each implanted probe due to implantation trauma and foreign body tissue response5,7,13,39–
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42. Due to these challenges, the usage of CNPs has been restricted to research settings, and they 
have only rarely seen application within human patients. 
 
 
 
 
  
Figure 1.1:  Examples of neural interface devices.  a) EEG head-net (From Russell et al.43 © Elsevier. 
Reprinted with permission).  b) ECoG electrodes on brain surface (From Schalk et al.44 ©2011  IEEE. 
Reprinted with permission).  c) Intracortical microwire array. (From Nicolelis et al.16 ©2003 National 
Academy of Sciences, USA. Reprinted with permission). 
 
 
 
1.1.1   Historical Overview 
 
The ability to chronically record the activity of neurons within the brain of a living animal 
requires the consideration of a number of key issues, including the extremely small size of the 
neurons in question as well as the constant motion of the tissue45. Prior to 1950, existing 
techniques could not be used as they required fine control and direct contact with the neurons 
being recorded. However, in 1958, Strumwasser published a method that allowed recording to be 
performed using electrodes in the vicinity of but not physically touching targeted neurons, which 
he used to perform long-term recording from the brains of anesthetized hibernating ground 
squirrels using 80 µm insulated stainless steel microelectrodes46. This method allowed him to 
record the activity of individual neurons for periods of over a week, while previous methods 
limited single neuron recording time to only a few hours46. 
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The first chronic intracortical recording implants consisted of arrays of fine insulated 
stainless steel, tungsten, or platinum/iridium wires either cut or etched to reveal a recording 
surface at the tip47–49. Insulators used for these initial electrodes typically consisted of crudely-
applied enamel, lacquer, or solder-glass. These initial fabrication methods commonly resulted in 
a large degree of variability between electrode tips, though these problems were later addressed 
by improved fabrication techniques and insulation methods50–52. Electrodes of this type were 
initially implanted individually, and were found to be capable of recording from single 
neurons53,54. This type of implant (Fig. 1.2a) has often been considered the de facto gold standard 
for chronic recording due to its low cost, ease of fabrication, and long history of use. 
 In 1970, Wise et al. took advantage of integrated-circuit fabrication techniques to 
introduce a completely different type of electrode incorporating a gold microwire embedded 
within a photoengraved silicon substrate55. These electrodes provide an interesting alternative to 
microwires, as the ease and flexibility of the photoengraving process allows for the production of 
a wide variety of embodiments and geometries, including the ability to localize multiple 
independent recording surfaces on the same shank at different depths15,45,56,57. This technology 
formed the basis of a commonly used intracortical electrode variety often known as the 
“Michigan” probe due to the institution of its development58 (Fig. 1.2b). 
 A third type of commonly used intracortical recording implant is the silicon 
microelectrode array (Fig. 1.2c), first described by Jones et al. in 199259, and then optimized and 
characterized in subsequent studies39,60–62. This type of array is practically similar to the 
microwire array, only in place of parallel wires it is produced by machining a solid block of 
silicon into a square cluster of vertical columns, which are then etched into sharp probes. These 
sharp silicon probes are then coated with layered platinum and titanium/tungsten and then 
5 
 
insulated using polyimide, which is removed at the tip to produce the recording surface. These 
devices were produced with the goal of maximizing the density of electrodes per unit area in as 
precise and reproducible a manner as possible, and also provide a large degree of customizability 
with regard to electrode spacing, geometry, and electrical characteristics. 
Work performed in this dissertation employed an advanced variety of microwire array 
known as the floating microwire array63, or FMA (Fig. 1.2d). This type of array features a 
flexible cable connector, which provides the array with an additional degree of mobility when 
implanted into cortex and allows it to drift with brain motion, unlike less sophisticated varieties 
which are adhered directly to the skull. The concept for this design originated with Gualtierotti 
and Bailey in 196863,64, who proposed a “neutral buoyancy” electrode with a flexible lead wire. 
 
 
 
 
  
Figure 1.2:  Examples of intracortical electrodes.  a) Microwire array.  b) Planar silicon array, from 
Kipke et al12.  c) Silicon multielectrode array, from Rousche and Normann39.  d) Floating 
microelectrode array. (a and d © Microprobes for Life Science, Inc. Used with permission. b © 
Journal of Neuroscience. Reprinted with permission, conveyed through Copyright Clearance 
Center, Inc. c © Elsevier, Reprinted with permission). 
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1.1.2   Basic Electrode Theory 
 
An in-depth discussion on the electrochemical behavior of the electrode/electrolyte interface has 
been published by Merrill et al.65, and is summarized within this section: 
In order to function, electrodes implanted with the intention of stimulating tissue or 
recording neural activity must transduce the electric current within the lead wire into an ionic 
current within the surrounding electrolyte (in this case, the extracellular fluid) and vice versa45. 
This transduction of current at the metal/electrolyte interface is fundamentally accomplished 
through two parallel and competing mechanisms: faradaic current, and capacitive current65 (Fig. 
1.3). Faradaic current occurs whenever an element of charge directly crosses the 
electrode/electrolyte interface, typically by way of a chemical reaction. These chemical reactions 
can take many forms, including but not limited to: the disassociation of metal atoms into 
positively-charged metal cations, the hydrolysis of water into oxygen or hydrogen gas, and the 
generation of new chemical compounds at the interface such as metal oxide65. 
 
 
Figure 1.3:  Mechanisms of faradaic and capacitive current.  a) Faradaic charge injection.  b) Capacitive 
charge injection.  c) Equivalent circuit model of the interface, demonstrating parallel capacitive and 
faradaic current paths (All figures ©  Bareket-Keren and Hanein66, Reprinted under CC). 
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For many types of electrodes, such as silver/silver chloride reference electrodes (where 
the formation and dissolution of silver chloride occurs readily and reversibly), faradaic current is 
intended to dominate the transduction process and will not cause any significant damage or 
chemical change to the electrode surface. However, for other types of electrodes and in certain 
stimulus conditions, extensive faradaic current will result in electrode corrosion, metal loss, 
tissue damage, or harmful gas evolution65. A number of example cathodic reactions include: 
Cu2+ + 2e- ↔ Cu    (metal deposition) (1.1) 
Fe3+ + e- ↔ Fe2+    (electron transfer) (1.2) 
2H2O + 2e- → H2↑ + 2OH-    (reduction of water) (1.3) 
IrO + 2H+ + 2e- ↔ Ir + H2O    (oxide reduction) (1.4) 
Pt + H+ + e- ↔ Pt-H    (hydrogen plating ‘pseudocapacitance’) (1.5) 
AgCl ↔ Ag+ + Cl-    (dissolution of silver chloride) (1.6) 
Example anodic reactions include: 
Fe → Fe2+ + 2e-    (metal anodic dissolution) (1.7) 
2Ag + 2OH- ↔ Ag2O + H2O + 2e-    (oxide formation) (1.8) 
2Cl- → Cl2↑ + 2e-    (gas evolution) (1.9) 
2H2O → O2↑ + 4H+ + 4e-    (oxidation of water) (1.10) 
Pt + 4Cl- → [PtCl4]2- + 2e-    (platinum corrosion) (1.11) 
Note that these reduction and oxidation reactions will only occur when it is thermodynamically 
and kinetically favorable for them to do so, and often require specific pH conditions, interfacial 
potentials, and reactant concentrations for them to proceed at an appreciable rate. Also, note that 
many of these reactions are potentially reversible, as reactive species may remain bound or close 
to the interface surface, though the reverse reactions may be only favorable outside of the normal 
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operating conditions of the electrode. Representative irreversible reactions are also provided, 
such as the hydrolysis reactions which produce evolved gas. These reactions are considered 
particularly undesirable within the context of intracortical electrodes, as they can result in  
undesired local pH changes, gas bubbles, or harmful chemical species65. 
 Capacitive current is generated from electrostatic repulsive and attractive forces acting 
between ions and electric charges building up on either surface of the electrode/electrolyte 
interface, resulting in a redistribution of charged species within the electrolyte. This 
redistribution of charge results in a phenomenon referred to as the electrical double layer (Fig. 
1.4), or the stacking of negative and positive charged species at the interface65. These charged 
species are further separated by layers of polar molecules such as water which preferentially 
orient themselves at the interface surface, as well as by adsorbed species such as halide anions. 
In the absence of faradaic current mechanisms the interface may be electrically modeled as a 
simple capacitor, typically referred to as the double layer capacitor CDL, and has a degree of 
frequency response defined by the time constant of this capacitor, which represents the saturation 
 
 
Figure 1.4: The electrical double layer. Schematic and associated potential profile normal to the 
electrode surface (Figure by Daiguji67, © 2004 American Chemical Society. Reprinted with permission). 
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 of charged species at the interface surface. As capacitive current is generated purely through the 
reorganization of charge carriers within the electrode and electrolyte and does not involve any 
chemical change to the interface, the transduction process will not harm or degrade the electrode 
surface. However, this mechanism is subject to limitations, as it can only conduct up to a limited 
charge density and is also dependent on the rate of potential change65. 
 Current moving from the electrode to the electrolyte or vice versa is subjected to a 
change in electrical potential at the electrode/electrolyte interface, within a very narrow 
interphase region65. This change in potential produces an electric field at the interface, measured 
in V/m. At equilibrium conditions and in the absence of current, this interfacial potential is 
known as a half-cell potential, and is a representation of the thermodynamic driving force for 
principal species at the electrode interface to undergo oxidation or reduction; typically, the 
dissolution of the electrode metal into electrolyte through oxidation at the anode, or the 
deposition of metal by way of the reduction of ionic species at the cathode. At standard state (1 
atm, 25° C, 1 mol dm-3 solute concentration), this potential is known as the standard electrode 
potential, though the effective half-cell potential of an interface at non-standard conditions can 
be calculated from the standard electrode potential using the Nernst equation65: 
𝐸𝑒𝑞 = 𝐸Θ + �𝑅𝑇𝑛𝐹� ln �[O][R]� (1.12) 
where Eeq is the equilibrium half-cell potential, EΘ is the standard electrode potential, R is the gas 
constant, T is the absolute temperature, F is Faraday’s constant, and [O] and [R] are electrolyte 
concentrations of oxidized and reduced species, respectively. If current is driven across the 
interface, the interface potential will be forced away from the equilibrium potential, with the 
difference being known as the overpotential. An electrode with an interface potential forced 
away from its equilibrium potential is generally referred to as being polarized.65 
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 Theoretical electrode interfaces are commonly modeled as being either purely capacitive, 
often called perfectly polarizing, or purely faradaic, known as non-polarizing. In reality, 
electrode interfaces present some degree of both capacitive and faradaic character. The degrees 
of capacitive current and faradaic current transduced across an interface upon connection with a  
voltage source are dependent on several factors, including charge density, the magnitude of the 
potential applied and the rate of change of that potential, and the kinetics and mass transport 
limitations of the reduction/oxidation reactions available at the interface. These factors dictate 
the resistance to current flow of each mechanism, which in turn determines the proportion of 
current flow through either capacitive or faradaic pathways. In the case of most intracortical 
electrodes featuring blocking metals such as platinum and slow faradaic kinetics, current will be 
principally transduced through capacitance up to some limiting charge density, at which point 
faradaic mechanisms will transduce the excess. At large potential magnitudes, this faradaic 
mechanism will often be either the reduction or oxidation of water, due to the lack of mass 
transport restriction owing to the abundance of water in the electrode environment. As the 
hydrolysis of water can be very damaging to surrounding tissue, its avoidance is a major aspect 
of stimulation safety, with stimulation paradigms designed to remain within the “water window”, 
or the range of potentials wherein the hydrolysis of water is thermodynamically unfavorable 
(typically between -0.6 V to 0.6 V)65,68. 
As the magnitudes of interfacial potential and current expected to be encountered during 
the normal operation of neural recording electrodes and stimulation electrodes are quite different 
from each other, the design concerns of each electrode are distinctive68. Neural recording 
electrodes, designed to detect and record the action potentials of nearby neurons, are typically 
only exposed to overpotentials well under 1 mV and thus remain very close to equilibrium68. 
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These electrodes are typically fabricated with the goal of achieving a specific impedance range in 
order to maximize signal-to-noise ratio (SNR) of recording, with higher impedance electrodes 
being expected to exhibit lower signal-to-noise ratios68,69. Recording electrode impedance is 
typically modulated through changes to surface area or through coatings such as oxide activation 
or conducting polymers. In contrast, electrodes designed for neural stimulation are expected to 
endure much larger current densities at elevated potentials. Thus, an important element of 
stimulation electrode and stimulus paradigm design is the minimization of harmful faradaic 
reactions, in particular the hydrolysis of water and the corrosion of metal65,68. As stimulation is 
additionally being applied to neural recording electrodes as well for a growing number of 
applications, including the drug release mechanism studied in this dissertation, these same safety 
considerations must be applied. 
 
 
1.2   REACTIVE TISSUE RESPONSE 
 
Upon implantation of an intracortical recording electrode into the brain of a living subject, a 
complex multi-faceted inflammatory tissue response is initiated as a consequence70. This 
response evolved as a protective mechanism, allowing the host body to detect and isolate foreign 
objects and resume homeostasis after injury. However, as a key element of this response is the 
encapsulation of the foreign body with reactive glia and extracellular material, it is thought that 
the process may play a principal role in the large inconsistency of recording performance 
observed among chronically implanted neural probes5,9–11,13,21,37–40,42,68,71–73. 
 This chronic performance inconsistency is typically characterized as a gradual and highly 
variable reduction in the number of units observed by each channel over time (a ‘unit’ being 
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common terminology for a set of recorded waveforms sorted together with a certain degree of 
confidence and thought to represent the firing activity of a single local neuron) (Fig.1.5). The 
loss of unit activity is coupled with a general reduction in recording quality measures, such as the 
increase of impedance and decrease of SNR of remaining units19,21,38,74,75. These effects are 
thought to correlate with a number of key tissue inflammatory response mechanisms7–
9,21,38,41,70,73,76, making the attenuation or elimination of these mechanisms a primary goal in 
electrode development and research. 
 
 
Figure 1.5:  Chronic variability and loss of recorded unit activity from implanted neural probes.  a) 
Examples of animals that demonstrated consistent chronic recording performance.  b) Examples of 
animals that demonstrated poor chronic performance. (Figures from Williams et al.10 © Elsevier. 
Reprinted with permission). 
 
 
 
1.2.1   Overview 
 
 
Healthy uninjured adult cortical tissue is populated by a variety of cell types, principally various 
types of neurons and an assortment of glia including astroglia, oligodendrocytes, and microglia 
(numerical densities being approximately 120,000 neurons/mm3, 38,000 astroglia/mm3, 17,000 
oligos/mm3, and 4,000 microglia/mm3 in adult macaque visual cortex77). Astroglia and microglia 
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typically exist in a restive, ramified state in bulk healthy cortex, with astroglia serving a large 
number of essential roles including blood flow regulation, neuron metabolic support, 
maintenance of ionic balance, transmitter regulation, and active participation in synaptic function 
and plasticity78–80. Microglia are monocyte-lineage cells that serve a monitoring role, constantly 
probing cortical tissue for damaged neurons, plaques, and pathological agents using an extensive 
arborization of processes73,81–86. Both cell types are extremely sensitive to disturbances in central 
nervous system (CNS) homeostasis and readily respond to all forms of tissue insult or disease. 
The cortex is additionally populated by a number of other cell types including oligodendrocyte 
precursor cells, stem cells, pericytes, and mast cells87,88. 
When initiated by the insertion of a foreign body such as an intracortical electrode, the 
tissue inflammatory response within cortex is thought to occur in two distinct yet interrelated 
phases (Fig. 1.6): the acute phase and the chronic phase. The acute phase, which persists from 
the moment of implantation to roughly one to two weeks post-implantation, is characterized by 
the activation of nearby microglia, astroglia, and other immune cells, coupled with the rapid 
necrotic or apoptotic death of local neurons, forming a “kill zone”7,13,89. This kill zone has been 
observed to vary in size between 10 and 100 µm from the probe surface, and appears to be 
dependent on the degree of initial trauma and intensity of the subsequent inflammatory 
response7,13,38. As detectable spikes are typically generated by neuron cell bodies within 50 µm 
and no more than 130 µm13,89,90 from the recording surface, this acute neuronal death can 
theoretically detract from recording performance13,75. However, in practice, the acute death of 
neurons following implantation was not observed to significantly impede recording7,89. 
Regardless, the acute response is thought to be mediated by the initial implantation trauma, 
vasculature damage, tissue edema, and the adsorption of protein on the implant surface72,73,91.  
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Figure 1.6:  Illustration of the phases of reactive cell response. The acute phase (A) characterizes tissue 
response within the initial 1-2 weeks post-implantation, while the chronic phase (B) characterizes tissue 
response at later time points. Note chronic accumulation and compaction of astroglia at the probe 
interface into an encapsulating glial sheath, as well as reduced neuron density within probe vicinity 
(Illustration from Schwartz et al.5 © Elsevier. Reprinted with permission). 
 
 
The chronic phase begins roughly two weeks post-implantation and persists for the 
duration of implant presence, and is typically characterized by foreign body response leading to 
the formation and stabilization of a dense astroglial sheath around the tissue/implant interface 
between two to three weeks post-implantation7,13,40,41,76,92 (Fig. 1.7), the extent of which has been 
correlated with increased 1 kHz impedance magnitude41. This impedance increase may be a 
consequence of the increased tortuosity of the encapsulating astroglia, which acts as a barrier to 
the diffusion of ions through the extracellular space93. The chronic phase is also characterized by 
the progressive degeneration and death of neurons local to the implant7–9,38. 
Further complicating the situation is the fact that the brain is immunologically privileged 
and shielded from the general immune system by the blood-brain barrier (BBB), which in 
healthy brain restricts the entry of circulating immunoglobin and lymphocytes in addition to 
bacteria, serum protein, and many drugs. As a consequence, brain tissue features its own 
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distinctive immune mechanisms that in many ways mirror the inflammatory responses elsewhere 
in the body, though with different cellular players. Intracortical implants may act as a chronic 
insult to this barrier through the rupture of nearby vasculature or the migration of meningeal cells 
or microbes from non-protected areas into cortex by way of the implant shaft38,72,73,94–96. 
 
 
1.2.2   Implantation Trauma and Provisional Matrix Formation 
 
At the moment of electrode implantation into cortical tissue, a number of key events occur which 
initiate and modulate the acute inflammatory response, as well as many aspects of the chronic 
response. Typically, electrodes or electrode arrays are surgically inserted through the pia and into 
 
Figure 1.7:  Typical astroglial sheath at 4 weeks post-implantation. Note inner core of activated microglia 
(ED1) surrounded by a dense lamellar astroglial layer (GFAP). Also note reduced density of neuron cell 
bodies (NeuN) and axons (NF) within 200 μm of probe surface. (Image from Biran et al.7 © Elsevier. 
Reprinted with permission). 
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cortex through a craniotomy following the sectioning and retraction of dura. The amount of 
trauma inflicted during this insertion is dependent on many variables, including insertion speed, 
location, and probe shape and size72,91,97–100. As the probe is driven into tissue it inflicts a host of 
traumatic events including the lysing of cells and cell processes, the rupture of vasculature both 
local and up to 300 µm distant from the probe tip72,91, the long-lasting disturbance of local 
BBB101, the tearing of extracellular matrix, and the dragging of meningeal tissue from the pial 
surface into the cortex94,96. However, despite the extensive and multimodal nature of this injury, 
cortical lesions have been observed to heal to a state nearly homogenous with surrounding 
healthy tissue after 1-2 months following clean microprobe stabs7,13,102 with substantially 
reduced neuronal loss7–9 if the probe is immediately removed following insertion (Fig. 1.8).  
 Rupture of local vasculature during probe insertion releases a bloom of plasma exudate 
into cortical tissue, bypassing the blood-brain barrier72,73,91. Among the circulating elements 
contained within this exudate are erythrocytes and leukocytes, clotting factors, immunoglobin, 
complement proteins, and an assortment of inflammatory factors and blood proteins5,13,40,73,92,103. 
Many of these cells and factors immediately begin interacting with CNS tissue and the probe 
surface, and a layer of protein instantly adheres to the probe surface forming a provisional matrix 
in a process commonly known as bio-fouling38. This provisional matrix, principally composed of 
albumin, fibrinogen, complement, fibronectin, vitronectin, and immunoglobin, represents the 
initiation of the thrombus/blood clot at the interface and is rich with active mitogens, 
chemoattractants, cytokines, growth factors, and other bioactive agents103,104. The provisional 
matrix in many ways directs the acute inflammatory response and healing process, contributing 
structural, cellular, and biochemical components, modulating microglial activation, and 
promoting the recruitment, proliferation, and activation of multiple other cell types38,73. The 
17 
 
matrix also serves as the principle point of contact by which local cells detect and adhere to the 
implant surface.103 
 
 
Figure 1.8:  Response to stab and implant. Tissue response to stab (ACEG) and chronic electrode implant 
(BDFH) in rat cortex at 2 (ABEF) and 4 (CDGH) weeks. ABCD are microglia (ED1) and EFGH are astroglia 
(GFAP). SB = 100 μm (Images from Biran et al.7 © Elsevier. Reprinted with permission). 
 
 
 
1.2.3   Consequences of Vascular Rupture 
 
Despite the rapid clotting of ruptured vasculature post-implantation, the initial introduction of 
exudate into the lesion area has a number of long-lasting consequences. Mechanically, a 
principal effect of vascular damage and BBB leakage is the generation of vasogenic brain edema 
and resulting cytotoxic swelling due to fluid buildup and pressure13,72. This edema has been 
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observed to persist for over a week post-implantation and generates a number of abnormal tissue 
consequences72. Ruptured vessels can also lead to loss of perfusion and ischemia downstream of 
the insult72,105. Additionally, vascular rupture not only initiates the inflammatory pathways but 
also a number of other protein cascades including the extrinsic and intrinsic coagulation systems, 
the complement system, the fibrinolytic system, the kinin-generating system, and platelet 
activation103, which may each play a role in the dynamic adsorption and desorption of protein at 
the interface. In addition to these various cascades, a number of circulating blood components 
are known to interact directly with neurons and glia; a prominent example being albumin, the 
most abundant plasma protein, which has been shown to reversibly increase calcium activity in 
glia and to also adversely affect neurons and astrocytes72. 
After clotting, a substantial number of residual extravasated erythrocytes remain in the 
cortical tissue and degenerate through hemolysis, releasing heme into the lesion environment92. 
This heme is subsequently degraded by the heme oxidase enzymes into iron, carbon monoxide, 
and biliverdin, which is then further converted into bilirubin by biliverdin reductase. This 
mechanism can cause harm to the local neuron population through both iron-induced oxidative 
stress as well as the neurotoxic properties of bilirubin. This process is known to play a significant 
role in tissue outcome following hemorrhagic stroke and traumatic brain injury88,106 and 
erythrocyte breakdown products have been observed surrounding probes after six weeks post-
implantation92, though it should also be noted that cortical micro-hemorrhage alone was found to 
be incapable of causing neural or dendritic degeneration when inflicted by a femtosecond laser 
pulse107. Instead, it may be interpreted that the process is contributing additional stress to the 
inflammatory environment. 
 
19 
 
1.2.4   Acute Inflammatory Response 
 
The hallmark of the acute inflammatory response following probe implantation is the activation 
of an assortment of inflammatory cell types both through the infiltration of leukocytes and 
through the activation of native glia73,108. Elsewhere in the body, the acute response to trauma is 
dominated by the activity of polymorphonuclear leukocytes103: principally neutrophils and to a 
lesser extent eosinophils and basophils. However, the access of these cells to an injury site in 
CNS is severely restricted following clotting, due to blood-brain barrier exclusion. Despite this 
barrier, neutrophils are observed in hematoma and surrounding cortical tissue at the earliest time 
points following intracerebral hemorrhage88,109 can damage tissue directly through the release of 
reactive oxygen species and pro-inflammatory proteases, as well as modulate BBB permeability 
and potentially aggravate neuron death88. Once extravasated into the brain, neutrophils will 
typically die by apoptosis within two days, though their death can cause further tissue damage as 
their contents stimulate nearby microglia to secrete toxic factors88. Microglia have been observed 
to phagocytize neutrophils within CNS before autolysis as a defense mechanism, staving off 
further damage110. 
 Microglia serve as the principal actors in the CNS acute inflammatory response and are 
the first non-neuronal cell type to exhibit a response to implantation trauma, having been 
observed using two-photon microscopy to react immediately upon probe implantation through 
the extension of processes toward the probe surface73. Within 24 hours, the microglia activate to 
an amoeboid locomotive state and undergo a number of morphological and functional 
transformations, including the enlargement of the cell body, thickening of processes, and the 
upregulation of a number of pro-inflammatory proteins. The microglia become proliferative, 
migratory, and phagocytotic73,108,111, rapidly surrounding the implanted probe and consolidating 
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themselves into a thin cellular sheath over the following week13,40,112. The role of the activated 
microglia is multi-fold, and includes the elimination of hematoma and tissue debris as well as the 
degradation of foreign bodies13,83,86. Large foreign bodies are encapsulated through a process 
called frustrated phagocytosis whereupon multiple microglia fuse into multi-nucleated “giant 
cells” which then envelop the foreign surface13. In addition, activated microglia express and 
release a variety of other potentially toxic factors including cytokines (in particular IL-1α, IL-1β, 
and TNF-α), chemokines, chondroitin sulfate proteoglycans, reactive oxygen species, proteases, 
prostaglandins, cyclooxygenase-2, and heme oxidase88,109,111, and are thought to broadly 
orchestrate the entire inflammatory response. 
 Circulating monocytes that infiltrate at the lesion site rapidly activate, whereupon they 
become essentially indistinguishable from microglia and effectively bolster their population88. 
Activated microglia also recruit additional circulating monocytes to the lesion site through the 
release of Monocyte Chemoattractant Protein-1 (MCP-1). Peak microglial activity is typically 
observed at 1-2 weeks post-implantation, though residual activity persists for a much greater 
period of time9,13,71. Of note is that while all activated microglia share morphological 
characteristics, a number of different phenotypes have been characterized which perform 
distinctive roles in the inflammatory response. The principal activated microglia phenotypes are 
M1, the “classical” subtype most responsible for pro-inflammatory cytokine release, and M2, an 
“alternatively activated” subtype responsible for response regulation and debris cleanup, which 
releases large amounts of the anti-inflammatory cytokines IL-10 and TGF-β113.  It is thought that 
these phenotypes work in concert to regulate the inflammatory response, making them an 
attractive target for therapeutic approaches (such as the selective inhibition of M1 phenotype 
polarization by minocycline114.  
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 A number of other cell types are thought to play roles in the acute inflammatory response, 
though their contributions have been less well studied. Mast cells, for example, are immune cells 
similar to basophils that are native to many tissues including CNS, and are capable of 
degranulating and releasing histamine and heparin, increasing edema and BBB permeability 
while slowing coagulation. These cells are typically primed with IgE to respond to a particular 
antigen, and are often dependent on the activity of T cells115. Despite this, the blocking of 
cerebral mast cells has been reported to reduce edema and hematoma volume following 
intracerebral hemorrhage with markedly improved outcomes, leading many to believe that the 
mast cell may play a more profound role in CNS inflammation than previously thought88. 
Perivascular macrophages are another CNS-resident inflammation sensitive cell, and are 
monocyte-lineage non-ramified macrophage-like cells that occupy space between the neural 
parenchyma and the vascular endothelial cells. They are implicated with hematopoietic cell 
infiltration into CNS when activated, as well as MHC expression and TNF-α, IL-1β, and iNOS 
production. In later stages after injury (2-3 weeks), they have been observed to leave their 
perivascular position and migrate into neural tissue where they differentiate into ramified 
microglia-like cells that retain strong MHC immunoreactivity108. 
 Other cell types known to infiltrate the CNS during cerebral hemorrhage events include 
lymphocytes such as T cells, which are known to play complex roles in inflammatory regulation 
and autoimmunity108,116–122. T cell-mediated autoimmunity is known to play a prominent role in 
several types of neurodegenerative pathology as well as hemorrhagic stroke and traumatic brain 
injury, though the healthy brain is typically well protected from this mechanism both by the BBB 
as well as neurons themselves, which suppress MHC expression in neighboring glia through 
interaction with the microglial CD200 receptor123. However, this suppression is strongly 
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dependent on neuron health and electrical activity, and CNS tissue inflicted with neuron damage 
or silencing has been observed to lose this protection as microglia resume MHC expression and 
antigen-presenting capability123. While this mechanism has been shown to play a role in large-
scale CNS hemorrhage, its relevance to microprobe implantation has not been well studied. 
 
1.2.5   Chronic Inflammatory Response 
 
While local astroglia initially activate at a very early time point post-implantation (often within 
24 hours of lesion108, commonly quantified by observing glial fibrillary acid protein (GFAP) 
expression), their distribution during the acute inflammatory period is sparse, with activation 
graded by distance from the lesion and the intensity of the initial trauma and acute response, up 
to around 500 μm from the implant surface. These astroglia are thought to be principally 
activated and directed by microglia-released cytokines, which tightly control the transformation 
of astroglia from protoplasmic to fibrillary form. Despite their early activation, astroglia exhibit a 
delayed response characterized by a slow migration to the implantation site, where they replace 
ensheathing microglia and enwrap local injured neurons with thin, flat processes40,108. This 
migration typically begins at 1-2 weeks post-implantation, characterized by an extension of 
astroglial processes toward the implant site. By three weeks, astrocytes will form an 
encapsulating sheath around the implant and nearby injured neurons, displacing microglia. The 
sheath grows increasingly compact and dense over time, though it is typically considered 
morphologically stable by the three week time point7,8,40,71. As it densifies, the interdigitating 
processes will adhere to each other, forming a multilayered stack of astrocytic lamellae 
surrounded by a network of extracellular matrix composed of tenascin, collagen IV, and 
chondroitin sulfate proteoglycans108. The development and maturation of the glial sheath is 
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known to be directed by a number of pro- and anti-inflammatory factors87,88,108. A more detailed 
description of the roles of astroglial scar in neuroinhibition and degeneration will be discussed 
within chapter 2 of this dissertation. 
 The chronic inflammatory response period is also characterized by the progressive loss of 
recordable units, as described within the overview above. For many years, this performance loss 
was thought to be a consequence of astroglial sheath development; however, more recent studies 
have observed that the initial signs of unit loss do not synchronize with the peak time point of 
astrogliosis, instead lagging roughly one month behind it8,9. This unit loss is currently thought to 
be due to the progressive degeneration and death of neurons local (within ~100μm) to the probe 
surface, which initially worsens by week 8 post-implantation and persists for the duration of 
probe implantation, based on existing long term recording studies5,11,13,16,21,37–39,42. Neural 
degeneration and the resulting unit loss both exhibit a large degree of inconsistency and 
variability between probes and across time points, as well as non-uniformity around the same 
probe124, though a correlation has been observed between neural degeneration and inflammation 
intensity8. It was also observed that different mechanisms of degeneration may play roles at 
different time points, with neuron and dendritic loss occurring by week 8 post-implantation, and 
axonal pathology by way of hyperphosphorylation of protein tau occurring after 16 weeks8. 
Demyelination (Fig 1.9) was also observed to occur in axons over 100 µm from the implant 
surface71,124, though the effect did not appear to be uniformly distributed around the probe. 
 This neuronal degeneration is thought to result from a complex series of interrelated and 
cross-modulating neurotoxic factors and environmental stressors which combine to disturb the 
delicate homeostatic and signaling balance required for neuron survival8,9 and drive local 
microglia, astroglia, and other cell types to convert from anti-inflammatory regulatory to pro-
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inflammatory reactive states. While acute neuronal loss is likely due to a combination of factors 
which result from implantation trauma and acute inflammatory response, including direct cell 
lysis, edema, oxidative stress, bilirubin toxicity, ischemia, acidosis, reactive microglial attack, 
CSPG-mediated inhibition, and pro-inflammatory cytokine and chemokine influence. Chronic 
degeneration on the other hand is likely due to self-perpetuating neurotoxic cytokine cascades 
coupled with mechanical stress due to probe micromotion and mechanical mismatch, vascular 
pulsation and damage, and other unknown factors. This progressive neurodegeneration was 
observed to continue at far chronic (16 week) time points, despite minimal microglial activation, 
stable and compact astroglial sheath, and little observable BBB leakage9. 
 
 
 
Figure 1.9:  Demyelination observed around an implanted electrode in rat cortex at 12 weeks. Yellow is 
Myelin-Oligodendrocyte Specific Protein (MOSP), and red is neurofilament. SB = 100 μm. (Image from 
Winslow et al.124 © Elsevier. Reprinted with permission). 
 
 
 
1.3   DISSERTATION ORGANIZATION 
 
This dissertation studies two approaches to studying and modulating the inflammatory response 
to implantable intracortical neural interfaces and advances the concept and theory behind 
25 
 
controllable drug-release coatings and glial sheath modification. Chapter 3 includes a research 
study that is in preparation for submission to a peer-reviewed journal, and chapter 4 includes 
work that will serve as the foundation for a second study. 
 In chapter 2, we discuss the development of an in vivo model for the evaluation of the 
impact of the microinjection of the bacterial enzyme chondroitinase ABC (ChABC) on the 
astroglial sheath around implanted probes. Chondroitinase therapy is an experimental treatment 
involving the enzymatic digestion of chondroitin sulfate proteoglycans (CSPGs) from a CNS 
injury location, and has been applied with varying degrees of success to both spinal and brain 
injury models125,126. CSPGs are known to possess strong neural inhibitory signaling capabilities, 
and are thought to be a principal component of the barrier to neural regeneration across glial 
scar. The benefits that ChABC therapy may offer to the chronically-implanted intracortical 
electrode model have not yet been studied. This work describes the development of an 
intracortical ChABC microinjection model, and the study of the effects of ChABC 
microinjection to the glial scar that had evolved around the implanted indwelling injection 
cannula itself. The results demonstrate the successful digestion of CSPG around the injection 
cannula, as well as its effect on local serum protein content. Results also suggest that cellular 
morphology and activation within the sheath did not appear substantially affected. Our 
observations concurred with those published elsewhere127 that CSPG expression peaks at 1 week 
post-implantation and rapidly diminishes thereafter, as we observed no discriminable CSPG 
signal at 18 days post-implantation. 
 In chapter 3, we study the neurophysiological recording capabilities, impedance 
characteristics, and drug releasing capabilities of a multiwalled-carbon nanotube (MWCNT)-
doped PEDOT coating loaded with the anti-inflammatory corticosteroid dexamethasone. As 
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discussed earlier, PEDOT has recently grown in popularity as an enhancement to chronic 
recording and stimulating microelectrodes due to its impedance-reducing capabilities and 
excellent electrochemical stability and charge storage capacity. PEDOT may also be employed 
as a controllable drug-releasing apparatus through the incorporation of a drug molecule as a 
counter-ion dopant. This drug-releasing capability has not been well evaluated in vivo. We 
studied the drug-release capacity of a PEDOT coating further modified with a MWCNT co-
dopant intended to increase polymer surface area and drug yield. Following characterization and 
coating optimization, we coated the recording surfaces of platinum-iridium floating 
microelectrode arrays (FMAs) and chronically implanted them into rat visual cortex for an 11 
day period. Drug release stimulation, neurophysiological recording, and impedance measurement 
were performed daily. Results demonstrated that the drug release stimulus was effective and did 
not result in atypical inflammatory response, changes to local neural activity, or substantial 
immediate changes to 1 kHz impedance. Coated probes demonstrated neurophysiological 
recording capability equivalent to that of uncoated probes. 1 kHz impedance of coated probes 
was observed to remain depressed for the initial 3 days post-implantation, but was then seen to 
increase rapidly and with distinctive phase characteristics to a point where it became statistically 
indistinguishable from uncoated probes by day 7 post-implantation. 
 In chapter 4, we discuss the development of an equivalent circuit model to better evaluate 
and interpret this in vivo impedance data. As the interface incorporates elements of both the 
conducting polymer coating as well as the evolving inflammatory tissue response, it presents a 
complex set of interrelated interfacial components that change dynamically with time. As most 
commonly-used simple models were found to be incapable of consistently fitting the recorded in 
vivo data, we adapted a more sophisticated transmission-line diffusion model to provide better 
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representations of the various physical correlates. Fitting results suggest that uncoated and coated 
chronic impedance behavior was driven by two very different mechanisms, with uncoated 
electrode impedance more a function of subtle changes to metal surface features and high-
frequency diffusion barrier development, while coated electrodes demonstrated large decreases 
of conducting polymer and electrode capacitance, likely a consequence of reduced effective 
surface area due to tissue encapsulation. 
 Chapter 5 summarizes the conclusions of the previous chapters and presents them in 
terms of their impact to the field of neural engineering. Additionally, it discusses new directions 
for research and opportunities for the application of techniques developed in this work. 
  
28 
 
  
 
2.0   THE DEGRADATION OF GLIAL SCAR THROUGH THE LOCAL DELIVERY OF 
CHONDROITINASE ABC 
 
 
2.1   INTRODUCTION 
 
As discussed in chapter 1 of this dissertation, perhaps the most detrimental aspect of the 
inflammatory response to the reliable long-term function of chronic intracortical recording 
electrodes is the progressive silencing, degeneration, and death of local neurons7–9,38. The 
mechanisms that lead to this neuronal loss are complex and interrelated, and are likely the 
product of a variety of environmental, biological, chemical, and mechanical stressors, many of 
which are unknown or not well understood. These stressors combine to disrupt the homeostatic 
balance necessary for neuron health and activity, leading to the degeneration and death of 
neurons or their migration away from the implant site. Informed electrode design and 
implantation techniques will likely be required to compensate for a majority of these stressors to 
maintain a healthy, active population of local neurons and achieve long-lasting and consistent 
recording performance72. This need can be seen reflected in a number of recent electrode 
concepts, such as ultrafine probes38 which strive to minimize mechanical strain, vascular 
damage, and surface area to present as unobtrusive an implant as possible. 
 A principal inhibitory barrier to neural healing and regeneration in CNS at the 
implant/tissue interface is the astroglial sheath. While astroglial scarring has been known to be 
an antagonist to axonal regeneration and healing within spinal cord for over sixty years, it was 
originally thought to be a purely mechanical blockade87,128. Later observations revealed that a 
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spinal lesion is capable of repelling regenerating axons even in the absence of dense glial scar, 
suggesting that more complicated biochemical factors may be at play87,129. It is now known that 
the astroglial sheath presents a rich neuro-inhibitory environment composed of both secreted 
soluble factors as well as extra-cellular matrix (ECM) signaling components87, and serves an 
important role as a restrictive barrier between healthy and damaged tissue, isolating the lesion 
and limiting the volume of inflammation130. However, despite these protective properties, 
hypertrophic astrocytes within the sheath also restrict the ability of neurons to regenerate and 
regain some degree of connectivity across the scarred lesion. Important to note is that the 
astroglial scar is by no means the only barrier to neuronal regeneration within the healing lesion, 
as a host of other components are known to provide considerable inhibitory signaling as well, 
including damaged oligodendrocytes and myelin debris131. Hypertrophic astrocytes within the 
glial scar inhibit neuronal ingrowth through a variety of mechanisms, including the upregulation 
of factors including tenascin, ephrin-B2, semaphorin 3, slit proteins, and an assortment of 
chondroitin sulfate proteoglycans (CSPGs)87. Of these candidates, the CSPGs have perhaps the 
most demonstrated ability to inhibit axonal regeneration125,132–136. 
CSPGs are a family of ECM proteins that play a diverse assortment of roles within the 
body, particularly in cartilage and scar tissue where they contribute structural integrity and 
compression resistance. Structurally, CSPGs consist of a core protein to which is covalently 
attached one or more chondroitin sulfate glycosaminoglycan (CS-GAG) sugar chains125,137. Each 
CS-GAG is composed of a linear unbranched chain of alternating monosaccharide units, D-
glucuronic acid and N-acetyl-D-galactoseamine, and is bound to the core protein by way of a 
Xyl-Gal-Gal-GlcA tetrasaccharide linking region to a serine residue137. The CS-GAGs are 
classified in terms of their sulfation, with the four known types (chondroitin sulfate A, C, D, and 
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E) being differentiated by the presence or lack of sulfate molecules at the 4 and 6 carbons of 
GalNAc and the 2 carbon of GlcA138 (Fig. 2.1). Additionally, a large variety of CSPGs have been 
classified in terms of core protein composition and CS-GAG length. The most common and 
relevant to CNS: aggrecan, brevican, versican, and neurocan (together collectively known as the 
lecticans) are large, bulky, aggregating proteoglycans that strongly interact with other ECM and 
membrane proteins through their highly charged sulfate groups. The lecticans are secreted by 
most glia and, despite existing at miniscule concentrations in healthy brain, nonetheless play a 
critical role as the major component of the perineuronal net, or the ECM network that surrounds 
neurons and stabilizes synapses139. They are also known to play a crucial part in development 
where they serve as “master regulators” of neuron migration, axon guidance, and neurite 
outgrowth140. Following CNS injury, the secretion of lecticans is greatly upregulated by reactive 
astroglia and microglia in the glial scar87 though at differential time points, with brevican, 
versican, and neurocan being expressed very early, peaking at one to two weeks and returning to 
baseline levels by four to eight weeks post-injury, while phosphacan was not observed to be 
expressed until four weeks post-injury, peaking at roughly two months141. 
 An important tool in studying the function of CSPG in CNS has been chondroitinase 
(Fig. 2.2), a bacterial enzyme that acts by cleaving the linkage between disaccharide units within 
the CS-GAG side chains, effectively stripping them from the CSPG core protein. Chondroitinase 
exists in a number of different forms, each specific to the sulfation state of the CS-GAGs it is 
capable of cleaving. The most universal, chondroitinase ABC (ChABC), is able to cleave CS-A, 
CS-C, as well as dermatan sulfate. By using chondroitinase to selectively degrade CSPGs, the 
mechanisms of their inhibitory influence on neurons and axon growth cones have been further 
elucidated and found to be multi-modal. Microinjection of ChABC into lesioned spinal cord was 
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Figure 2.1: Structure of constituent CS-GAG disaccharide. Illustration demonstrates placement of sulfate 
groups for known chondroitin sulfate variants (Diagram by Galtrey and Fawcett 2007142, © Elsevier. 
Reprinted with permission). 
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shown to cleave CS-GAGs from CSPG in vivo, and produced enhanced axonal 
regeneration125,134,135. Similar microinjections in healthy cerebellum143, hippocampus144, cuneate 
nucleus145, and spinal cord146 produced enhanced neurite sprouting and local plasticity. 
Paradoxically, earlier work in vitro observed that while both intact CNS-derived CSPGs and 
stripped CSPG core proteins were able to dose-dependently inhibit outgrowth from cultured 
neuronal PC12D cells, unbound CS-GAGs had no discernible effect even at high 
concentrations147, suggesting that much of the neuromodulatory ability of CSPG may depend on 
the concerted contributions of several CSPG and ECM components. For example, it was found 
that while explanted rat glial scar tissue treated with ChABC demonstrated increased neurite 
outgrowth, this enhancement was partially reversed when the ChABC-treated explant was 
subsequently exposed to anti-laminin antibody133. 
 
Later work revealed a number of direct receptor-mediated inhibitory pathways between 
CSPGs and neurons, including epidermal growth factor receptor (EGFR)-mediated increase in 
 
 
Figure 2.2:  Rendering of the bacterial enzyme chondroitinase ABC. Demonstrates binding with 
dermatan sulfate (Figure from Prabhakar148, © 2005 Biochemical Society. Reprinted with permission). 
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calcium levels in affected cells149, interactions with protein tyrosine phosphatase sigma (PTPσ) 
receptors125, and the activation of Rho-kinase, which results in growth cone collapse150. Studies 
targeting these pathways have reported success in negating the inhibitory properties of 
CSPG149,151. These inhibitory mechanisms also appear dependent on the sulfation state of the CS-
GAG constituents of CSPG, and it was shown that the down-regulation of sulfotransferase 
resulted in greatly reduced neural inhibition137. Additionally, ChABC treatment is thought to 
provide additional benefits through the creation of disaccharide digestion products, which are 
known to promote neurite outgrowth and neuroprotection in local neurons and microglia152. 
Due to these benefits and few apparent negative consequences, ChABC treatment has 
become a popular direction in spinal and brain regeneration research125. Typical studies have 
taken one of two approaches: either the direct administration of ChABC to the lesion site, 
sometimes in conjunction with a bridge or graft125,134–136,153–159, or the administration of ChABC 
to an uninjured nucleus upstream from a lesion, with the goal of digesting perineuronal nets and 
“unlocking” neurons to promote enhanced plasticity145,146. The former approach was first 
explored by Lemons et al. in 1999154, who first demonstrated the enhanced production of CSPGs 
following spinal contusion, as well as the digestion of those CSPGs in vivo by way of a local 
ChABC injection. In 2001, Moon et al. demonstrated the regeneration of CNS axons following 
ChABC injection to a nigrostriatal lesion155. Bradbury et al. demonstrated partial functional 
recovery following ChABC treatment to a spinal lesion in 2002134. Subsequently, an assortment 
of studies has been performed demonstrating degrees of functional recovery following ChABC 
treatment to a variety of CNS lesion locations125. However, a number of limitations have also 
been observed. While ChABC treatment has been effective in promoting recovery following 
slicing injuries, its benefit following more clinically relevant pinching and contusional injuries 
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has been limited, in both spinal cord158 and brain126. Garcia-Alias et al. observed that while axons 
were regenerated following ChABC treatment administered seven days following spinal injury, 
functional recovery was reduced compared to animals where ChABC was administered 
immediately following injury160. There has additionally been some question regarding the 
susceptibility of ChABC to thermal degradation. While Tester et al.159 observed a significant 
reduction in ChABC activity in vitro within three days at 37° C, Lin et al.156 demonstrated 
continued ChABC digestion in CNS in vivo 10 days after a single injection. 
While ChABC treatment has been extensively employed in spinal and brain lesions, its 
applicability to chronically implanted devices has not been well studied. As discussed in chapter 
1 of this dissertation, while the inflammatory tissue responses to an acute lesion and to an 
implanted probe share many common elements, they have many differences as well. While both 
situations exhibit similar patterns and time courses of CSPG expression (peaking at 1 week and 
gradually returning to baseline by 3-4 weeks), chronic astroglial and microglial activation is 
significantly more pronounced around the chronic implant, suggesting a richer pro-inflammatory 
environment. The purpose of this study was to develop an effective model for ChABC injection 
into CNS by way of a chronically implanted cannula. The effect of ChABC digestion was then 
observed within the tissue response to the cannula itself. We later coupled the cannulae with 
recording electrodes physically adhered to the cannulae surfaces to study chronic impedance 
changes following ChABC treatment, in preparation for the next phase of study where cannulae 
would be implanted in parallel with a multielectrode array. While this next phase has not yet 
been initiated, this chapter serves to chronicle the successes and challenges faced during the 
development of the injection model. 
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2.2   EXPERIMENTAL 
 
This study was carried out as a series of developmental and optimization steps with the goal of 
developing an effective model of ChABC microinjection for use in subsequent studies as a 
component of a microelectrode array. Common methods utilized throughout the study are 
detailed within this section, while a narrative of model development is provided in section 2.3. 
 
2.2.1   Surgical Implantation 
 
Infusion cannulae, including the model employed in this study, typically feature a guide cannula 
which is implanted into tissue and a separate injector cannula which is slid inside the guide 
cannula to perform the actual infusion at the time of injection. During implantation and until the 
time point of injection, an obdurator (typically a solid rod of plastic or steel of outer diameter 
matching the inner diameter of the guide cannula) is placed inside the guide to close it, 
preventing tissue ingrowth and infiltration of contamination. 
Throughout this study, guide cannulae were implanted either unilaterally or bilaterally 
into the parietal cortices of male Sprague Dawley rats under the guidelines of the University of 
Pittsburgh IACUC: Each animal was anesthetized under 3% isoflurane, weighed, and mounted 
onto a stereotaxic frame (Narishige USA, Inc., East Meadow NY). The top surface of the skull 
was exposed and a 2 mm diameter circular craniotomy centered at 1 mm post Bregma and 3.5 
mm lateral to midline was made using a high speed hand drill and fine rongeurs. Saline was 
applied continuously onto the skull to suppress heat from the high speed drilling. Four skull 
screws were mounted in a uniform arrangement around the craniotomies. Following dural 
puncture, stereotaxic insertion of each guide cannula (with obdurator inserted, EtO sterilized) 
was accomplished using a small clamp mounted to a hand-driven microdrive. Each cannula was 
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manually lowered at a consistent pace into cortex until the upper surface of the skull was 1 mm 
distant from the lower surface of the cannula head socket, resulting in a tissue depth of ~2 mm. 
With the cannula held firmly in place, the craniotomy was sealed using UV-cured dental cement 
(Pentron Clinical, Orange CA), liberally applied onto the cannula head socket and around nearby 
skull screws. Once both cannulae were in place, a robust head cap was molded in place using 
dental cement (Cerebond, Plastics One, Inc., Roanoke VA). A protective flexible plastic cap was 
adhered to the hardened cement using hot glue to provide additional protection to the guide 
cannula ports. Animal temperature was maintained throughout the procedure using a warm water 
pad (HTP 1500, Adroit Medical Systems, Loudon TN) and homeostasis was maintained using 
regular injections of sterile Ringer’s solution. 0.3mg/kg buprenorphine was administered twice 
daily for three days as a post-operative analgesic. Animals were provided with soft water-based 
diet gel immediately after surgery, and food and water were provided ad libidem for the 
remainder of the experiment. All animal care and procedures were performed under the approval 
of the University of Pittsburgh Institutional Animal Care and Use Committee and in accordance 
with regulations specified by the division of laboratory animal resources. 
 
2.2.2   Cannula Selection and Fabrication 
 
 
Initial work was performed to select and test an appropriate microinjection cannula. We initially 
selected a model available from Plastics One featuring a polyether ether ketone (PEEK) cannula 
tube with an externally-threaded head socket (Fig. 2.3a); however it was found that the screw-on 
obdurator cap did not leave enough clearance underneath to allow for the application of a 
sufficient amount of dental cement, and the trial animal was able to fracture the head cap. An 
alternate version of this cannula was procured which featured a flange on the lower surface of the 
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head socket, but during a trial implantation was found to be too awkward to position properly. 
Thus, the Plastics One model was abandoned. 
 In its place, we adopted polyurethane guide cannulae (OD: 550 μm, ID: 360 μm) 
produced by CMA Microdialysis AB (distributed in the USA by Harvard Apparatus, Hollison 
MA), sold as a component of a microdialysis probe (Fig. 2.3b). These cannulae feature a “cup” 
type head socket as opposed to the external threading of the previous model, which allows 
cement to be applied liberally around the cannula without risk if interference with cannula 
function, allowing for a simpler surgical procedure and a more robust head cap. Initial attempts 
were made to fashion an injector cannula by carefully cutting the dialysis tip off of a probe, but 
this yielded unacceptable resistance to fluid flow. Instead, an injector was hand-made using 28 
gauge SS hypodermic tubing which was cut to a convenient length and deburred. The injector 
was bonded to flexible PTFE tubing using epoxy, and injector length was set using small plastic 
spacers. 
 
 
 
 
Figure 2.3: Example commercial guide cannulae. a) Plastics One model (© Plastics One Inc., used with 
permission).  b) CMA models, demonstrating “cup” head socket and insertible obdurators. Small murine 
model on right was employed in this study (© CMA Microdialysis AB, used with permission).  
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2.2.3   Microinjection 
 
Microinjection procedures were typically performed either 10 or 18 days post-implantation, to 
capture either the period of peak CSPG expression, or the period of peak astroglial sheath 
development. During the injection procedure, the animal was sedated using 3% isoflurane, and 
placed onto a microwaveable warming pad. The protective plastic cap was carefully removed, 
exposing cannulae ports. The obdurator of the guide cannula through which injection was 
performed was removed and placed into a 70% ethanol bath for cleaning. The injector was 
ethanol sterilized and connected to a 10 μL glass syringe (Hamilton Co., Reno NV), and tubing 
was pre-charged with either sterile saline or mineral oil (for enzyme or antibody injection). 4 μL 
of treatment solution was drawn into the injector tip, and the injector was slid into the guide 
cannula port until the tip of the injector was flush with the end of the guide. The Hamilton 
syringe was mounted onto an electronically-controlled syringe pump (Fisher Scientific, Waltham 
MA), and injection was performed at a rate of 6 μL/hour for 20 minutes. Similar injection rates 
and volumes have been employed in other cortical microinjection studies161–163. After the 
injection was completed, the injector was removed and the obdurator replaced. Animals 
scheduled for immediate histology were allowed to rest for an additional 40 minutes to allow for 
enzyme diffusion and activity before perfusion. Generally, in bilateral cannula-implanted 
animals, one side was used for experimental injection and the other side for control 
(bacteriostatic 0.9% sodium chloride, Hospira, Inc., Lake Forest IL). 
 Chondroitinase ABC used for injection was purchased in lyophilized powder form 
(Sigma-Aldrich, St. Louis MO) and was dialyzed and diluted to a working concentration of 100 
U/mL before being aliquoted and frozen. Bioactivity of each batch was evaluated using sectioned 
chicken embryo. 
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2.2.4   Dye-labeled Antibody Infusion Test 
 
To determine the approximate volume and pattern of enzyme penetration within tissue following 
microinjection, a test was performed by way of the substitution of Alexa488-labeled antibody (2 
mg/mL goat anti-rabbit, Invitrogen). Eighteen days after cannula implantation, microinjection of 
2 µL of labeled antibody solution was performed as described above, except that following the 
40-minute post-injection period the animal was immediately euthanized and the brain was 
removed without fixative perfusion. After removal, the brain was immersed into 4% 
paraformaldehyde for five minutes and flash-frozen by immersion in liquid nitrogen-cooled 
isopentane. The brain was blocked, cut into 20 μm sections, and imaged using a fluorescence 
microscope to observe the extent of antibody penetration. 
 
2.2.5   Hybrid Cannula/Electrode Study 
 
A preliminary study was performed to evaluate the impedance changes exhibited by electrodes 
following chondroitinase ABC treatment. Simple electrode/cannula implants were hand-
fabricated by adhering two tungsten microwire electrodes (Microprobes for Life Science, 
Gaithersburg MD) to opposite sides of CMA cannulae using UV-activated cement (Fig. 2.4). The 
initial array was fabricated with electrodes flush against the sides of the cannula to attempt to 
maximize the exposure to enzyme, but later arrays were fabricated with electrodes spaced 
roughly 1mm lateral from the cannula tip. Electrode impedance was assessed in PBS using a 
potentiostat (Fas1 Femtostat, Gamry Instruments, Warminster PA) before EtO sterilization. 
Implantation was performed as in 2.2.1 above, only with a larger craniotomy to accommodate 
the electrodes. Periodic impedance measurement was performed before and after injections. 
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 2.2.6   Histology 
 
At select days post-implantation, animals were sacrificed and perfused according to University 
of Pittsburgh IACUC approved methods. Each animal was deeply anesthetized using 65 mg/kg 
ketamine, 7 mg/kg xylazine cocktail. Once the proper plane of anesthesia was observed, animals 
were transcardially perfused using a warm PBS flush followed by ice cold 4% 
paraformaldehyde. Animals were decapitated and heads were post-fixed in a 4% 
paraformaldehyde bath at 20°C overnight. Following post-fix, the skull was dissected and 
cannulae carefully removed to avoid incidental tissue damage. Whole brains were then removed 
and soaked in a 15% sucrose bath at 20°C overnight followed by a 30% sucrose bath until brains 
were fully impregnated. Brains were then blocked and carefully frozen using a 20% 
sucrose/OCT blocking media blend and dry ice. Tissue was typically sagittally sectioned parallel 
to the axis of the cannulae using a 14 μm section thickness. 
Tissue sections were hydrated using PBS and exposed to a 0.5 mM CuSO4 solution for 10 
minutes to reduce hemosiderin-dependent autofluorescence164. Following exposure, sections 
were washed with PBS (3x5min) and incubated in a blocking solution (10% goat serum, 3% 
 
 
Figure 2.4: A hybrid cannula/electrode implant. Features 1 mm wire spacing from cannula. 
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triton X-100) for 1 hour at ambient temperature. Following blocking, sections were incubated in 
a primary antibody solution consisting of 5% goat serum, 1.5% triton X-100, and antibodies 
against microglia (1:200 mouse anti-IBA1 and anti-ED1, Abcam, Cambridge MA), astroglia 
(1:500 rabbit anti-GFAP, Dako, Glostrup, Denmark), neurons (1:500 rabbit anti-NeuN and anti-
NF200, Invitrogen, Grand Island NY), immunoglobin (1:500 anti-IgG and anti-IgM, courtesy of 
Dr. Carl Lagenaur), and chondroitin sulfate GAG (hybridoma-derived CS56 antibody, courtesy 
of Dr. Willi Halfter) for 18 hours at 4°C. The next day, sections were washed with PBS (3x5min) 
and incubated in a secondary solution consisting of 5% goat serum, 1.5% triton X-100, and 
antibodies (1:1000 goat anti-mouse Alexa 488, Invitrogen, and 1:1000 goat anti-rabbit Alexa 
594, Invitrogen) for two hours at ambient temperature. Sections were then rinsed with PBS for 5 
minutes, exposed to 1:1000 Hoechst 33342 (Invitrogen) for 10 minutes, and washed in PBS (3x5 
minutes) before being coverslipped with Fluoromount-G (Southern Biotech, Birmingham AL). 
Sections were promptly imaged using fluorescence microscopy (Axioskop 2 MAT, Carl Zeiss, 
Inc., Oberkochen, Germany, equipped with an X-Cite 120 fluorescence illumination system, 
EXFO, Inc., Mississauga, Ontario). 
 
 
2.3   RESULTS AND DISCUSSION 
 
This study was undertaken to establish a “proof of concept” of the microinjection of ChABC into 
cortex through a chronically implanted cannula, to evaluate its effects and to resolve technical 
challenges before integration with more sophisticated recording systems. As such, it was 
performed as a series of trial implantations, each attempting to resolve principal challenges 
encountered in the previous trial through modifications to implant geometry, surgical or 
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microinjection technique, histology methods, and critical time points. This section will 
summarize a number of the more critical challenges as well as the resolutions applied, and will 
report on the performance of the final model protocol. 
 
2.3.1   Microinjection Technique 
 
Once an acceptable cannula design had been selected (as described in section 2.2.2), a study was 
performed to evaluate the extent of drug penetration into tissue following microinjection. Due to 
the size and nature of the cannula, it cannot be easily simplified to a point source for diffusion 
modeling due to the presence of significant backflow up the shank of the cannula. This backflow 
or “leak-back” of infusate up the cannula surface is due to a number of factors including local 
tissue damage, elastic deformation, and pressure gradients, and has been studied in detail165–168 as 
it is typically an undesirable feature of injection. However, as this study is specifically targeting 
the scar tissue around the cannula surface itself for treatment, infusate backflow is desired. 
 Injector cannulae are typically designed to extend a certain distance into tissue from the 
end of the guide cannula when inserted, infusing a bolus of fluid well below the guide cannula 
while also generating a fresh lesion in tissue. For the purposes of this study, the injector cannulae 
were fabricated significantly shorter, roughly 0.5mm short of the guide cannula tip, conceptually 
leading to significantly less strain and injury to tissue on injector insertion. To visualize the 
penetration profile of protein-laden infusate into tissue, a dye-labeled antibody infusion study 
was performed, as described in 2.2.4. IgG possesses only slightly higher MW than 
chondroitinase ABC (~150 kDa and ~120 kDa, respectively). Resulting images are shown in 
figure 2.5. Note lateral penetration of dye as well as prominent backflow pattern up cannula 
surface. Measurements indicate antibody penetration to roughly 1 mm from cannula at tip depth. 
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Figure 2.5: Dye penetration following microinjection. Composite image demonstrating the penetration 
of Alexa488-labeled IgG into cortical tissue following infusion of 2 µL sample. SB = 200 µm. 
 
 
2.3.2   Histology Methods 
 
Polymer guide cannulae were employed due to the possibility of sectioning being performed 
with cannulae in place within brain. However, early trials revealed that cannulae were only very 
loosely bound in tissue and would often slip out of the lesion during dissection or sectioning, 
making the method too inconsistent to employ for the remainder of the study. Early observations 
of tissue with intact cannulae revealed that the lesion conformed closely to the cannula surface. 
 Initial histology was performed using horizontal sections from the upper surface of the 
brain perpendicular to the cannula axis. While this method provided a large number of sections 
for labeling, it did not allow for the visualization of immunoreactivity expression gradients down 
the length of the cannula. Thus, sagittal sectioning was adopted, which allowed for the entirety of 
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the cannula to be observed within a single section (Fig. 2.6). As tissue at the cannula tips often 
demonstrated a large degree of irregularity due to the stresses of obdurator removal, a length of 
cannula wall within 1 mm of the cannula tip was selected for use in comparisons. 
 
 
 
Figure 2.6: Horizontal vs. Sagittal. a) Example horizontal section (GFAP).  b) Example composite sagittal 
section (ED1). Red box indicates typical area used for immunoreactivity comparison. SBs = 200 µm. 
 
 
2.3.3   Immunoreactivity Interference of Serum Immunoglobin 
 
Early ChABC injection and histology trials revealed an interesting phenomenon, in that 
secondary antibodies were able to bind to tissue features without primary antibody exposure. 
Moreover, this binding appeared to be attenuated by tissue ChABC exposure, and was specific to 
anti-mouse Ig (Fig. 2.7a&b). Binding occurred throughout the tissue, though it appeared to be 
concentrated within local cells (likely astroglia based on morphology) (Fig. 2.7c). As our anti- 
chondroitin sulfate GAG primary antibody (CS56) and several other immunolabels were derived 
from mouse hybridoma, this phenomenon had the potential to significantly confound 
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observations. Based on specificity of secondary antibodies involved, it was assumed that the 
mechanism of interference was the binding of anti-mouse Ig secondary antibody to rat serum Ig 
that had infiltrated the lesion site through blood brain barrier leakage since implantation. 
Sensitivity of this immunoreactivity to ChABC treatment was assumed to be due to this serum Ig 
being released from ECM following enzymatic digestion, which was later observed using anti-rat 
Ig labeling. To compensate for this issue, we acquired highly cross-adsorbed secondary 
antibodies. 
 
  
These antibodies appeared to substantially reduce but not completely eliminate the 
binding, effectively limiting the sensitivity of the labels. While chondroitin sulfate expression 
was sufficient at 10 days post-implant to overwhelm the serum Ig binding, at 18 days post-
implant it was not expressed strongly enough to allow for confident comparisons. To label 
chondroitin sulfate more specifically, it may be necessary to move to a lectin-based label such as 
wisteria floribunda agglutinin, though this was not performed during the course of this study. 
 
 
Figure 2.7:  Interference of released serum protein on CS labeling.  a) Immunoreactivity of alexa594-
labeled anti-mouse IgG secondary antibody with tissue in absence of primary antibody.  b) Comparative 
immunoreactivity of alexa594-labeled anti-rabbit IgM to the same tissue.  c) Example image 
demonstrating preferred binding within stellate structures at interface (likely astroglia).  SB = 200 µm. 
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2.3.4   Chondroitin Sulfate Digestion after ChABC Infusion 
 
Once the microinjection model was optimized to a satisfactory degree, we performed 
immunohistological imaging to characterize the inflammatory response at the cannula interface, 
and demonstrated the ability of the ChABC infusion to digest CS-GAG within the reactive 
tissue. Activated astroglial and microglial marker expression within the inflammatory tissue at 
10 and 18 days post-implantation appeared similar to typical responses observed around smaller 
probes, with a tight core of activated microglia at the tissue/cannula interface, and a more diffuse 
field of activated astroglia that was observed to condense at the interface at the later time point 
(Fig. 2.8). No visually apparent change was observed in microglial or astroglial marker 
expression 1 hour or 1 week after ChABC treatment. As discussed in 2.2.3 above, CS-GAG 
marker expression was prominent within the inflammatory region at 10 days but was not 
discernible at 18 days, which conforms to the known time course of lectican expression141. 
 ChABC infusion resulted in an immediate reduction in 10-day CS-GAG marker 
expression in inflammatory tissue around the cannula consistent with enzymatic digestion (Fig. 
2.9a). It was also observed to result in an immediate reduction in both rat IgG (Fig. 2.9b) and 
IgM (Fig. 2.9c) local to the cannula, presumably due to release of trapped serum Ig within the 
ECM. 
 
2.3.5   Hybrid Electrode-Cannula Implant Performance 
 
As mentioned in section 2.2.5, two initial electrode-cannula hybrid devices were fabricated and 
implanted bilaterally into rat parietal cortex. These devices were fashioned such the electrodes 
were flush against the side of the central cannula in order to ensure exposure to infused solution. 
However, upon comparing subsequent impedance measurements over the ongoing days post-
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implantation, three of the four electrodes did not exhibit the characteristic increase in 1 kHz 
impedance typically observed around implanted electrodes and remained nearly flat for the 
entirety of the initial 24 day pre-injection period, as well as through the course of injections. 
 
 
 
Figure 2.8:  Glial sheath formation. Expression of activated microglial (ED1) and astroglial (GFAP) 
markers along the cannula/tissue interface at two time points. Note consolidation of both cell types into 
a compressed layer at the cannula surface. SB = 100 µm. 
 
 
Upon experiment completion and probe explantation, it was observed that the electrode 
that had exhibited normal impedance behavior had actually separated from the surface of the 
cannula during implantation by roughly 1 mm. Based on this, it was speculated that the current 
path of the other three electrodes had shunted up the outer surface of the cannula and thus 
bypassed the tissue response entirely, resulting in low, steady-state impedance characteristics. 
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Figure 2.9:  Digestion and serum protein. Effect of 2 µL (6 µL/hr) 100 U/mL ChABC versus saline control 
infusion on a) CS-GAG (CS56), b) IgG, and c) IgM after one hour post-infusion. Cannulae implanted for 10 
days pre-infusion. Enzyme injection visibly reduced expression of all three markers. SB = 100 µm. 
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In light of these observations, a second pair of electrode-cannula implants was prepared 
with electrodes spaced 1 mm from each cannula. Probes were implanted and allowed to develop 
a response for 22 days, with periodic impedance measurement. On the 22th day, both cannulae 
received a saline control infusion. Following this, impedance was measured daily for four days at 
which point a ChABC infusion was applied to both cannulae. 
 
 
Figure 2.10:  Impedance measurement of a cannula-electrode hybrid probe. “Pre” represents pre-
implantation impedance in PBS, “day 1” is the probe impedance the day of implantation, and “postinj” is 
impedance measured 1 hour following injection on days 23 and 27. 
 
 
A record of impedance measurements at 1 and 3 kHz for a representative electrode is 
shown in figure 2.10. It was hypothesized that CS-GAG may contribute to electrode impedance 
by acting as a barrier to ionic diffusion within the ECM of the glial scar, and that digesting it 
with ChABC would thus eliminate its contribution. However, it was observed that impedance of 
the electrode reduced immediately after both saline control and ChABC infusion, and returned to 
previous levels within one day. As 1 kHz impedance was extremely variable throughout the trial, 
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as apparent within the record, a large number of additional repetitions would be required to 
evaluate changes with statistical confidence. However, this single trial suggests that ChABC 
treatment may not lead to a chronic effect on electrode impedance. The immediate drop in 
impedance following both infusions is speculated to be due to a momentary swelling of tissue 
with infusate. 
 While these probes had the potential to provide interesting dynamic impedance 
information, the technical difficulties involved in their fabrication and use made them 
impractical for anything beyond a pilot study. Electrode spacing could not be carefully controlled 
with the fabrication tools available, and the cement bond was prone to mechanical failure. 
Additionally, only two electrodes could be placed around each cannula, greatly limiting study 
efficiency. A superior option would be to incorporate an injection cannula into a commercially-
available multi-electrode array, which would allow for measurement and recording from a 
plethora of precisely-positioned electrodes with each treatment. 
 
 
2.4   CONCLUSION 
 
During the course of this study we were able to develop and demonstrate a model for the 
infusion of chondroitinase ABC into cortex. A number of design and application challenges were 
encountered and circumvented through modifications to hardware and techniques. The model 
should be easily adaptable to a more sophisticated electrode array/injector system that will allow 
for a more profound analysis of the effects of CS-GAG digestion on inflammatory tissue 
response, electrode impedance, and neurophysiological recording performance. 
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3.0    IN VIVO ELECTRICAL STIMULATION OF A DEXAMETHASONE-RELEASING 
PEDOT/MWCNT NEURAL ELECTRODE COATING 
 
 
3.1   INTRODUCTION 
 
 
Neural prostheses have seen effective use in a variety of applications, including auditory 
prostheses, visual prostheses, and brain-computer interface1–3,5,6,68. Several examples employ 
arrays of penetrating microelectrodes that are implanted into cortex to record neural activity with 
single cell resolution1,5,12,15,16,37,39,58. When chronically implanted, these electrodes typically 
suffer a large degree of variability and deterioration of recording performance metrics such as 
single-unit yield and signal-to-noise ratio over months to years21. Such unreliable recording 
performance has become a principal obstacle against the more widespread clinical translation of 
intracortical electrodes. The large degree of variability and degradation are thought to be a 
product of several factors both abiotic and biotic13,21.  Principal among these factors is the degree 
of tissue inflammation elicited by electrode implantation and chronic presence. Several 
interrelated inflammation mechanisms including the development of an encapsulating glial scar 
and the degeneration and death of local neurons have been theorized to play important roles in 
this recording quality deterioration7–9,13,38,40,71–73,92,169. 
In light of these observations, novel intracortical electrode design has largely focused on 
improving probe electrical characteristics170, reducing tissue reactivity through changes to 
electrode geometry38,171–173, flexibility174–177, and surface properties124, employing biomaterial 
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strategies to promote tissue stability38,178–183, and incorporating drug release systems to introduce 
anti-inflammatory agents127. While drug release systems intended for intracortical electrode 
integration have typically been limited to microfluidics or slow-release gels and coatings, 
systems utilizing conducting polymers have been explored due to their on-demand release 
capabilities184,185.  
Drug delivery from conducting polymers generally involves the incorporation of the drug 
into the conducting polymer as a dopant that is then released using an applied electrical 
stimulus186. The basis of this capability is the ability of the conductive polymer to “switch” from 
a charged oxidized state to a neutral reduced state upon application of a current pulse with 
voltage sufficient to cross the reduction potential of the material. Small charged species 
introduced as a counter-ion to the oxidized conducting polymer are released once the coating is 
converted to its neutral state, whereupon they diffuse into the surrounding environment. This 
mechanism may be used to release a wide variety of species, including anionic, cationic187,188, 
and neutral189. The selection of dopant has also been shown to have an effect on other electrode 
properties such as biocompatibility and in vitro neuron survival190. 
While drug release through conducting polymer stimulation has been extensively studied 
in vitro (as reviewed by Svirskis 2010186), the translation of this technology in vivo has been 
limited. The bulk of research has focused on the conducting polymer polypyrrole (PPy), due to 
its well characterized synthesis, morphology, and release performance. However, there are a 
number of detrimental aspects of Ppy that limit its applicability to chronic in vivo applications191. 
These include a significant degree of α-β’ coupling which leads to structural disorder, limited 
electrochemical response, and over-oxidation susceptibility192, as well as a vulnerability to 
biological reducing agents such as glutathione and dithiothreitol193. An alternative is poly(3,4-
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ethylenedioxythiophene) (PEDOT), which has been shown to possess significantly improved 
electrochemical stability191,194,195 and electrolyte compatibility196. PEDOT has been successfully 
integrated onto chronic intracortical recording electrodes in a number of studies191,197–208. 
The application of PEDOT onto microelectrode recording surfaces has been shown to 
provide a number of intriguing electrochemical benefits in a manner that is simple, cost effective, 
and applicable to most existing electrode designs191,197. PEDOT has been shown to significantly 
reduce probe impedance without substantially increasing site geometric surface area, and can be 
applied using electrochemical synthesis directly onto the recording site surface191,197–200. PEDOT 
has also been shown to allow for highly reversible charge injection, and significantly increases 
charge storage capacity compared to uncoated surfaces202,204,206,209–211. Additionally, PEDOT 
coatings have demonstrated good electrical stability after both repeated stimulation 
pulsation195,209,211,212 and chronic warm PBS bath immersion213. These properties have proven 
translatable to in vivo application, and studies featuring the chronic implantation of PEDOT-
coated probes show that the coated probes exhibited lower impedance and improved recording 
characteristics when compared to uncoated controls200,201,203,204. The PEDOT coatings have also 
been shown to elicit tissue reaction comparable to bare platinum following short term (two week) 
implantation207. 
Despite its promise, the use of PEDOT for drug release applications has been limited 
compared to PPy. Abidian et al.185 employed a different release strategy using the mechanical 
actuation of PEDOT nanotubes to “squeeze out” trapped drug within the tubes. Alternatively, 
release quantity may be increased through the synthesis of a porous or sponge-like film 
morphology, such as that demonstrated by our group using Ppy214,215. Our work takes a different 
approach, through the use of a multi-walled carbon nanotube (MWCNT) co-dopant216,217 to 
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maximize exposed polymer surface area. Benefits of this approach include the mechanical 
reinforcement of polymer by the carbon nanotubes (CNTs)208 as well as the ability of the CNTs 
to act as a nano-reservoir of drug218. CNTs have been successfully integrated onto neural 
electrodes both alone through direct electro-deposition219 or as a dopant within a polymer 
composite205,208,220. Our group has previously shown that doping PPy films with MWCNT allows 
for significantly greater drug release than from PPy alone218. The study presented here expands 
on that previous work by improving chemical and electrochemical stability through the 
replacement of PPy with PEDOT. 
The purpose of the work presented within this chapter is to demonstrate in vivo the 
feasibility of an electro-polymerized PEDOT drug delivery system featuring a MWCNT co-
dopant and to perform a short-term performance comparison of this system against implanted 
uncoated Pt/Ir electrodes. Our model drug for release was dexamethasone sodium phosphate, 
selected due to its well-characterized utility in attenuating acute-phase inflammation127,221 as well 
as its anionic character, allowing it to serve as a dopant without the need for intermediate carrier 
molecules. Dexamethasone possesses a well-characterized ability to attenuate acute-phase CNS 
inflammation127,221 and has previously been explored as a candidate molecule for conducting 
polymer release in vitro in studies that demonstrated the controllability, consistency, and yield of 
the release method184,185,218. Our work employed several methods including complex impedance 
spectroscopy, equivalent circuit analysis, cyclic voltammetry, neurophysiological recording, and 
tissue histology to demonstrate both the safety and functionality of the drug release system as 
well as the ability of the coated probes to record neural activity effectively. 
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3.2   EXPERIMENTAL 
 
3.2.1   Carbon Nanotube Preparation 
 
Multi-walled carbon nanotubes were purchased (OD 20-30 nm, ID 5-10 nm, length 10-30 µm, 
purity >95%, Cheap Tubes Inc., Brattleboro VT) and functionalized using a previously published 
method218. In summary, 200 mg of nanotubes were sonicated for two hours at ambient 
temperature in an acid bath consisting of 100 mL 1:3 ratio of concentrated HNO3 and H2SO4 
(Sigma-Aldrich Co., St. Louis MO). The solution was then gently stirred at ambient temperature 
for 12 hours. Treated nanotubes were collected by decantation following ultracentrifugation 
(16,000 RPM at 15°C for 40 minutes) and sonicated for 10 minutes in diH2O (Milli-Q, Millipore 
Co., Billerica MA). Centrifugation and decantation were repeated until the pH of the supernatant 
was 6.0. The remaining solvent was evaporated off in an oven at 60°C. 
 
3.2.2   In Vitro Drug Release Characterization 
 
Gold macroelectrodes were fabricated using a custom-designed template featuring a 0.456 cm2 
electrode area. 0.51 mm thick polystyrene sheets (McMaster Carr Inc., Cleveland OH) were 
trimmed into 0.01 m2 rectangular tabs and cleaned by soaking in 7.9 M nitric acid (Sigma-
Aldrich) for 30 minutes at ambient temperature before being rinsed with diH2O and dried with 
nitrogen gas. Custom adhesive masks were prefabricated featuring holes for circular electrode 
surfaces and linear contact segments, and were adhered to the polystyrene before a 40 nm gold 
layer was applied using a sputter coater (108auto, Cressington Scientific, Watford, UK). 
Films were electropolymerized onto the gold macroelectrodes for drug release testing as 
follows: prepared acid-functionalized MWCNTs were dispersed and dexamethasone 21-
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phosphate disodium salt (Sigma-Aldrich) was dissolved into diH20 at a concentration of 1 
mg/mL and 20 mg/mL respectively, and sonicated for one hour to facilitate drug loading and 
uniform dispersion of the nanotubes. Post-sonication, 6 µL of 3,4-ethylenedioxythiophene 
(Sigma-Aldrich) was added to the solution and triturated until dissolved. The gold 
macroelectrodes were then inserted into the solution and a film was electropolymerized using a 
three-electrode cell consisting of a platinum sheet counter and Ag/AgCl reference using a 
potentiostat (FAS 1 Femtostat, Gamry Instruments, Warminster PA). Polymerization was carried 
out at constant 1.2 V until a total charge of 46 mC was reached. Post-polymerization, the coated 
macroelectrodes were gently rinsed with diH2O and soaked in a gently stirred 2 L PBS bath 
overnight at ambient temperature, with the bath solution being refreshed after the first hour. 
Macroelectrodes were stored in an ambient temperature static PBS bath until release. 
Release quantification was conducted using a two electrode cell with a platinum sheet 
serving as the counter. Coated macroelectrodes (N=6) were individually clamped into glass 
cuvettes containing a 1 mL PBS bath, which was sampled for non-stimulated passive release 
every five minutes for 20 minutes. The concentration of dexamethasone within 100 μL samples 
was quantified using a plate reader (Spectramax M5, Molecular Devices, Sunnyvale CA) at a 
characteristic wavelength of 242 nm. Sampled solution was returned to the electrode bath after 
each measurement. Immediately after the passive release assessment, macroelectrodes were 
subjected to a stimulation routine as follows: cyclic voltammetry (20 cycles from 0.6 V to -0.9 V 
(vs. Pt) at 1 V/s anode-first) was applied to the electrode, and the bath was sampled and 
dexamethasone concentration quantified as above. Sampling was repeated once every five 
minutes until the concentration was found to remain stable. At this time, the 20-cycle CV 
stimulation pattern was applied twice, with a one minute resting period between individual sets 
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of cycles, and the sampling routine was performed as above. This was repeated a further three 
times, with the number of CV stimulation patterns increasing by one with each repetition, for a 
total of 15 CV stimulation patterns spread between five measurement sessions. This progressive 
assessment routine was performed to ensure that the dexamethasone concentration increase for 
each session remained within the sensitivity limit of the plate reader. The entire process was 
repeated with a separate set of electrodes (N=3), but with a more aggressive release stimulation 
(10 cycles of square wave stimulation, 2.0 V for 5 s, 0.0 V for 5 s. (vs. Pt)). 
 
3.2.3   In Vivo Array Preparation 
 
Floating Microelectrode Arrays (FMAs, Microprobes for Life Science) were removed from their 
commercial packaging and sterilized using an EtO gas sterilizer (AN 74i, Andersen Products, 
Inc., Haw River NC) after which they were transferred to a sterile environment within a 
biosafety cabinet. Initial quality-control impedance testing of all array sites was performed in a 
sterile PBS bath using a potentiostat (Autolab PGSTAT128N with FRA2 impedance 
spectroscopy module and Nova 1.8 control software, Metrohm USA, Riverview FL) with a three 
electrode setup consisting of a platinum wire counter and an Ag/AgCl wire reference (10 Hz-30 
kHz, 10 mV RMS). If recorded impedances differed substantially from manufacturer-reported 
impedances, the array was subjected to an electrochemical cleaning step (constant -2 V for 20s). 
After cleaning, the array was removed from solution and re-inserted to ensure no bubbles 
remained, and impedance was retaken. This cleaning process was repeated until the sites reached 
the impedances reported by the manufacturer. Following performance verification, each array 
was rinsed with diH2O and then immersed in a sterile polymerization solution prepared in the 
same manner as that used for the in vitro electrode preparation above. Using a three electrode 
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cell, half of the array sites were coated using constant 1.3 V (vs. Ag/AgCl) for 30 seconds, 
selected using a staggered, alternating arrangement to prevent positional bias in the array. After 
coating, the array was rinsed using diH2O and impedance measurement was repeated in sterile 
PBS. Arrays were allowed to continue soaking in PBS for 30 minutes to remove adsorbed drug, 
given a final rinse using diH2O, and were then stored dry in a sterile enclosure. Immediately 
before implantation, arrays were exposed to a UV sterilization lamp within a sterile biosafety 
cabinet for 30 minutes. 
Characterization was also carried out on single microwires (Pt/Ir alloy, 12 µm diameter, 
parylene-C insulated, 30 µm length exposed tip with ~380 µm2 area, Microprobes for Life 
Science, Gaithersburg MD) identical to those of the arrays implanted in vivo above. Individual 
electrodes were coated using the same protocol as in vivo arrays. Impedance spectroscopy was 
conducted in PBS using the potentiostat in a three-point configuration (10 Hz-100 kHz, 10 mV 
RMS). Scanning Electron Microscopy was conducted at The University of Pittsburgh’s Center 
for Biological Imaging on a field emission SEM (6335F, JEOL USA Inc., Peabody MA). 
Coating adhesion was evaluated by inserting and removing coated electrodes from Long Evans 
rat cortex in vivo or from an agarose gel using a micromanipulator. Coating integrity was 
evaluated using impedance spectroscopy and SEM. Agarose gel was prepared by heating a 
stirred 5 mg/mL agarose (Fisher Scientific, Waltham MA) solution to 85° C until clear, at which 
point it was allowed to cool and set. 
 
3.2.4   Surgical Implantation 
 
Prepared FMAs were implanted unilaterally into the right primary visual cortex, monocular area 
(V1M) of male Long Evans rats. Each animal was anesthetized under 3% isoflurane, weighed, 
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and mounted onto a stereotaxic frame (Narishige USA, Inc., East Meadow NY). The skull was 
exposed and a 3x3 mm rectangular craniotomy centered at 6.5 mm post Bregma and 3.5 mm 
lateral to midline was made over V1 using a high speed drill and fine rongeurs. Saline was 
applied continuously onto the skull to suppress heat from the high speed drilling. The dura was 
resected using fine Vannas scissors, and the brain surface was moistened using gelfoam while 
stereotaxic hardware was put into place. Insertion of the FMA array was accomplished using a 
vacuum suction tip mounted to a hand-driven manipulator (SM-11, Narishige USA, East 
Meadow NY). The craniotomy was sealed using a low-viscosity silicone222 (Dow Corning, 
Midland MI). Four skull screws were mounted around the craniotomy and a headcap was applied 
using UV-cured dental cement (Pentron Clinical, Orange CA) to secure the FMA connector and 
cable. Animal temperature was maintained throughout the procedure using a warm water pad 
(HTP 1500, Adroit Medical Systems, Loudon TN) and homeostasis was maintained using sterile 
Ringer’s solution. 0.3mg/kg buprenorphine was administered twice daily for three days as a post-
operative analgesic. Animals were provided with soft water-based diet gel immediately after 
surgery, and food and water were provided ad libidem for the remainder of the experiment. All 
animal care and procedures were performed under the approval of the University of Pittsburgh 
Institutional Animal Care and Use Committee and in accordance with regulations specified by 
the division of laboratory animal resources. 
 
3.2.5   Treatment Schedule 
 
Immediately after implantation and daily thereafter, animals were lightly anesthetized using 1-
3% isoflurane and subjected to a stimulation and recording protocol. All coated and uncoated 
array sites were subjected to an identical cyclic voltammetric stimulation program each session. 
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Before and after this stimulation, both spontaneous and evoked neural activity was recorded and 
complex impedance was measured across the entire array. This protocol allows all metrics to be 
measured immediately before and immediately after stimulation, and tracked daily for the 
duration of the experiment. Each component of the session is described in detail below: 
 
3.2.6   Drug Release Stimulation 
 
Electrical stimulation for drug release was performed using a PGSTAT128N potentiostat 
connected to a 16 channel multiplexer. Sequentially on each channel, cyclic voltammetry was 
performed using 20 cycles from -0.9 V to 0.6 V (two point vs. Pt. counter electrode) at a 1 V/s 
scan rate, anode-first. Redox behavior of each site was qualitatively observed in terms of 
reduction and oxidation peak height and potential shift. Fast-CV cathodic charge storage 
capacity and charge balance were computed by integrating the area under cathodic and anodic 
curves. Charge storage capacity was used to compute injected cathodic charge density for each 
pulse. 
 
3.2.7   Neurophysiological Recording 
 
Recording of spontaneous and visually evoked single units, multi-unit, and LFP response was 
performed each session, both before and after stimulation. Spontaneous recording was conducted 
in a dark room. During each recording session, animals were situated on a microwaveable 
heating pad inside of a darkened faraday cage while lightly anesthetized with isoflurane. An 
LCD screen was positioned outside of the cage and the animal’s head was fixed to provide for 
optimum viewing angle from the dominant eye. Optimum anesthetized activity levels were 
typically observed when isoflurane level was set at the very lowest concentration sufficient for 
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the maintenance of animal inactivity (1.5-1.75%). Subjects were carefully observed during 
recording to ensure the proper plane of anesthesia was maintained. Visual stimuli were presented 
using the MATLAB-based Psychophysics toolbox on an LCD monitor placed 20 cm from the 
eye contralateral to the implant. Solid black and white bar gratings were presented drifting in a 
perpendicular direction and synchronized with the recording system (RX5, Tucker-Davis 
Technologies, Alachua FL). Each 4 second grating presentation (rotated in 45° increments) was 
separated by a 4 second dark screen period. Additionally, a spiraling continuous stimulation with 
3°/s clockwise rotation was also presented each recording session.  The raw data stream was 
filtered to produce LFP (1-300 Hz) and spike (0.3-3 kHz) data streams. Possible spikes were 
detected using a fixed negative threshold value of 3.5 SD. Offline spike sorting was carried out 
using a custom MATLAB script. Average SNR (averaging the amplitudes of single units for 
each channel), and average amplitude of noise (4 SD) was used to quantify electrode recording 
performance. Only channels exhibiting detected spikes were included in the SNR computation. 
All parameters were compared for each group before and after stimulation, as well as at each 
time point. 
 
3.2.8   Impedance Spectroscopy and Equivalent Circuit Analysis 
 
Electrochemical impedance was measured before and after each stimulation session. While under 
anesthesia, the implanted array was connected to the Autolab potentiostat using a 16 channel 
multiplexer. Impedance was measured for each channel using a 10 mV RMS sine wave from 10 
Hz to 32 kHz, employing a 15 multisine paradigm to shorten the time required for measurement. 
MEISP (v3.0, Kumho, Seoul, South Korea) and NOVA (v1.8, Metrohm USA) were used for 
measurement and analyses.  
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3.2.9   Histology 
 
At 11 days post-implantation, animals were sacrificed and perfused according to University of 
Pittsburgh IACUC approved methods. Each animal was deeply anesthetized using 65 mg/kg 
ketamine, 7 mg/kg xylazine cocktail. Once the proper plane of anesthesia was observed, animals 
were transcardially perfused using a warm PBS flush followed by ice cold 4% 
paraformaldehyde. Animals were decapitated, and heads were post-fixed in a 4% 
paraformaldehyde bath at 20°C overnight. Following post-fix, the skull was dissected and 
electrode arrays carefully removed to avoid incidental tissue damage. Whole brains were then 
removed and soaked in a 15% sucrose bath at 20°C overnight followed by a 30% sucrose bath 
until brains were fully impregnated. Brains were then blocked and carefully frozen using a 20% 
sucrose/OCT blocking media blend and dry ice. Tissue was horizontally sectioned from the 
surface of the cortex down, perpendicular to the axis of the probes, using a 10 μm slice thickness. 
Sectioning continued until approximately 200 μm below the disappearance of the probe tracks to 
ensure that probe tips were captured. 
Tissue sections were hydrated using PBS and exposed to a 0.5 mM CuSO4 solution for 10 
minutes to reduce hemosiderin-dependent autofluorescence164. Following exposure, sections 
were washed with PBS (3x5min) and incubated in a blocking solution (10% goat serum, 3% 
triton X-100) for 1 hour at ambient temperature. Following blocking, sections were incubated in 
a primary antibody solution consisting of 5% goat serum, 1.5% triton X-100, and antibodies 
against microglia (1:200 mouse anti-OX42, Abcam) and astroglia (1:500 rabbit anti-GFAP, 
Dako, Glostrup, Denmark) for 18 hours at 4°C. The next day, sections were washed with PBS 
(3x5min) and incubated in a secondary solution consisting of 5% goat serum, 1.5% triton X-100, 
and antibodies (1:1000 goat anti-mouse Alexa 488, Invitrogen, and 1:1000 goat anti-rabbit Alexa 
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594, Invitrogen) for two hours at ambient temperature. Sections were then rinsed with PBS for 5 
minutes, exposed to 1:1000 Hoechst 33342 (Invitrogen) for 10 minutes, and washed in PBS (3x5 
minutes) before being coverslipped with Fluoromount-G (Southern Biotech, Birmingham AL). 
Sections were promptly imaged using confocal microscopy (FluoView 1000, Olympus, Inc.) at 
40X magnification with electrode sites centered in the imaging field. Confocal imaging was 
performed in a single session using identical laser power and detector gain for each channel. 
A custom MATLAB script was written to perform intensity-based radial analysis for 
activity dependent fluorescent markers (OX-42/GFAP). For the analysis, images were compared 
to control data >250 µm away from any insertion site. In order to prevent holes in the tissue 
(such as blood vessels and probe tracks) from artificially reducing the average activity-dependent 
fluorescence, background noise intensity threshold was calculated. To calculate the background 
noise intensity threshold, pixels with intensity greater than one standard deviation dimmer than 
mean pixel intensity were considered “signal” and removed from the calculation. The threshold 
was then determined by calculating the pixel intensity of one standard deviation below the mean 
of the remaining pixel intensities. After being loaded into MATLAB, the center of the probe 
track was identified on each image, after which the script generated masks of concentric rings 
every 20 µm for 240 µm. The average gray scale intensity for all pixels above the background 
noise intensity threshold in each 20 µm ring was calculated, normalized against the background, 
and plotted as a function of distance. Data were averaged for coated and uncoated locations. 
 
3.2.10   Explant Imaging 
 
Coating integrity of the explanted probes was evaluated using scanning electron microscopy. 
Following array extraction, electrodes were soaked in a 5% trypsin solution for twenty minutes 
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at ambient temperature to remove tissue residue and fully reveal the underlying coating surface. 
Arrays were then rinsed with DI water and dried for high resolution SEM. 
 
3.2.11   Statistics 
 
Comparison between two groups was performed using a student’s t-test, with α<0.01 considered 
a significant result. Comparison between multiple time points in the same group was performed 
using ANOVA with a Tamhane T2 post-hoc test. Tamhane T2 was selected in place of Tukey 
due to the large difference in variances within absorption spectroscopy and in vivo impedance 
data. 
 
 
3.3   RESULTS 
 
3.3.1   In Vitro Characterization 
 
Dexamethasone (Dex) and MWCNT-doped PEDOT coatings were characterized with regard to 
morphology, impedance, and drug release capacity (Fig. 3.1). Representative coated surface 
morphology is shown in figure 3.1a and b, demonstrating the fine, open, lattice-like morphology 
of the electrodeposited film. This is in contrast to typical uncoated microwires, which exhibit the 
coarse and irregular metal surface texture typical of arc-exposed electrode tips (Fig. 3.1c). The 
contrast demonstrated in the scanning electromicrographs illustrates the greatly increased surface 
area of the dex/MWCNT/PEDOT-coated surfaces. The impact of this increased surface area was 
observed using impedance measurement (Fig. 3.1d), which demonstrated that the coating 
significantly decreased (p=0.0003) the 1 kHz impedance modulus of the coated microwire tips 
(276 kΩ ± 147 kΩ) compared to those left uncoated (446 kΩ ± 153 kΩ) in PBS. Coating 
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adhesion testing demonstrated no apparent changes to electrode impedance or surface 
morphology following insertion and removal of a coated microwire from in vivo rat cortex. 
Insertion and removal of a coated microwire from agarose gel resulted in a clinging residue of 
agarose to the surface visible by SEM, but no change in electrode impedance. 
The controlled drug release characteristics of the coating were evaluated in vitro with 
coated gold macroelectrodes using a progressive stimulation routine. Peak stable release 
quantities for passive diffusion and passive diffusion plus 10 sets (20 CV cycles each) of 
stimulated release (N=6 for each) are shown in figure 3.1e. Passive release during 20 minutes of 
immersion in PBS produced a dexamethasone concentration significantly greater than PBS 
control (1.62 ± 0.84 μg/cm2 based on coated electrode surface area, p=0.001). Total cumulative 
dexamethasone release following passive diffusion and 10 sets of stimulated release was found 
to be significantly greater (3.68 ± 1.22 μg/cm2, p=0.009) than that released through passive 
release alone. Cumulative release from the second set of electrodes (N=3) subjected to a more 
aggressive release stimulation yielded a 115% increase in released drug (p=0.009). 
 
3.3.2   Electrochemical Impedance 
 
To compare the in vivo performance of dexamethasone/MWCNT-doped PEDOT-coated probes 
against conventional non-coated microwires, Long Evans rats were implanted with 16-channel 
floating microwire arrays unilaterally into V1 monocular cortex. The layout of the implanted 
arrays is illustrated (Fig. 3.2a), demonstrating the alternating staggered arrangement of the 
coated and uncoated probes. Comparisons between chronic in vivo impedance and charge storage 
were quantified (Fig. 3.2b-f). For all impedance and cyclic voltammetry measures, N=24 for 
days 0-3, but was reduced to N=16 for days 4-11, as a result of animal loss due to pneumonia. 
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 Figure 3.1: Morphology, impedance, and drug release. a-c) SEM images of (a) coated microelectrode (SB 
= 3 µm), (b) detail of coated microelectrode (SB = 0.5 µm), (c) uncoated microelectrode (SB = 3 µm). d) 1 
kHz impedance modulus comparison between coated and uncoated electrodes before implantation. e) 
Cumulative dexamethasone release following passive and passive plus stimulated release from coated 
gold macroelectrodes into 100 µL PBS bath. (N=6, box=25-75%, cross=mean, whiskers=SD). *: p<0.01. 
 
 
Day 0 data were collected on the same day as implantation, immediately after the surgical 
procedure was completed. Data for days 5, 6, and 9 are not displayed, as potentiostat failure 
during script execution prevented pre-stimulus data collection from at least one animal. 
Average daily pre-stimulation 1 kHz impedance modulus values for coated and uncoated 
probes are shown (Fig. 3.2b). Impedance of the coated probes was found to be significantly 
lower than values observed from uncoated probes for the first three days post-implantation 
(p<0.0001 for each day). Subsequently, the impedance of coated probes increased rapidly to the 
point that it became indistinguishable from uncoated values for the remainder of the experiment. 
Dynamic impedance behavior over the first three days of the experiment is shown in detail (Fig. 
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3.2c), which highlights that coated probe impedance values remained significantly  depressed 
compared to day 0 values for two days post-implantation (p=0.004 for day 0-1, p=0.007 for days 
0-2), while uncoated probes on average exhibited steadily increasing impedance values. Average 
impedance values of coated probes were significantly lower than uncoated probes in PBS and for 
the first three after implantation, and also significantly decreased for two days following 
implantation. 
Daily values for the average change in probe 1 kHz impedance measured immediately 
before drug release stimulation compared to those measured immediately after stimulation are 
shown (Fig. 3.2d). Average post-stimulation impedance values typically changed by a degree 
less than 10% of pre-stimulation values, with change usually trending in the negative direction. 
Additionally, a statistically significant difference between coated and uncoated post-stimulation 
1 kHz impedance change was only observed on days 0 and 1 (p=0.002 and 0.0001, respectively). 
 
3.3.3   Cyclic Voltammetry and Charge Storage Capacity 
 
Electrochemical properties of the deposited films were evaluated using daily drug release cyclic 
voltammetry profiles. 20 cycles between -0.9 V to 0.6 V at 1 V/s were applied to each channel 
daily and the resulting curves were used to characterize the chronic stability and charge capacity 
of the films in vivo. Typical in vivo release CV curves are displayed (Fig. 3.2e) for both coated 
and uncoated probes, with all channels from each group averaged from one animal and one day 
(day 1 post-implantation) and plotted within the same figure. Coated probes exhibited a 
reduction peak at -700 mV, while uncoated probes exhibited no reduction behavior. 
Average daily values of CV cathodic charge storage capacity (CSCC) are shown for both 
coated and uncoated probes (Fig. 3.2f). As expected from the curves shown in figure 3.2e, 
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average CSCC of coated probes remained roughly 300% greater than uncoated probes for the 
duration of the experiment. The difference was found to be statistically significant at each time 
point (p<0.01 for all measurements). Maximum injected cathodic charge was estimated to be 260 
μC/cm2 for uncoated probes and 600 μC/cm2 for coated probes (over ~1.5s) based on 
approximate geometrical surface area. Comparison between anodic and cathodic charge density 
of coated electrodes indicated charge balance of between 80% and 90% throughout the 
experiment, with charge surplus being in the anodic direction. 
 
 
Figure 3.2: In vivo impedance and charge capacity. a) FMA layout. Red = coated, and blue = uncoated. 
Black sites are 2.5 mm Pt/Ir ground and reference electrodes. b) Average 1 kHz in vivo impedance values 
for uncoated and coated probes, recorded daily immediately before application of release stimulus 
(N=24 for days 0-3, 16 for days 4-11). c) Detail of impedance values for coated probes during initial three 
days of implantation (N=24). d) Average % change in post-stimulus impedance compared to pre-
stimulus. e) Average CV curves collected from one animal at one day post-implant. Discontinuity 
indicates starting potential. f) Average cCSC computed from CV. Data presented as mean ± SD. *: p<0.01. 
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3.3.4   Neurophysiological Recording 
 
Contralateral monocular visual stimulation provided using an LCD monitor evoked robust firing 
rate change during the entire period of experimentation. A representative spike data stream from 
a coated channel on the last day of implantation, day 11 post-implantation, is shown in figure 
3.3a. The waveform, inter-spike interval histogram, and PSTH of a representative sorted single 
unit on this channel are presented in figure 3.3b-d. Average recording noise amplitude and SNR 
(signal to noise ratio) between the coated and uncoated electrodes are compared in figure 3.3e 
and f.  
 
 
Figure 3.3: Recording performance. a-d) Representative recorded neural activity for a coated electrode 
at day 11 post-implant, demonstrating typical unit characteristics. a) Filtered data stream (0.3-3 kHz), 
with red line indicating initiation of visual stimulus. b) Two example units from the same channel. c) 
Peristimulus time histogram for the example units. d) Interspike intervals for the example units. e) 
Average SNR values on representative days for coated and uncoated channels before and after CV. f) 
Average noise amplitude immediately before and after CV. Data presented as mean ± SD. p>0.01 for all. 
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Same-day unit information is divided into groups before and after CV stimulation to 
evaluate the influence of stimulation on neural activity. The results suggest that the recording 
performance and neural activity on each electrode were not altered by the release stimulation to a 
degree quantifiable by the methods used. Performance was also not observed to be correlated 
with impedance during the initial week, as uncoated and coated probes exhibited the same noise 
amplitude and SNR despite having significantly different 1 kHz impedance. In general, the 
coated channels performed similarly in comparison with non-coated channels. 
 
3.3.5   Histology 
 
Representative confocal images of GFAP and OX42 expression around coated and uncoated 
probe tips at 11 days post-implantation are shown (Fig. 3.4a and b). Highly variable but 
comparable degrees of astroglial and microglial response were observed around each probe type. 
Average fluorescent intensity analysis performed in one animal revealed no significant 
difference in the expression of either GFAP or OX42 between coated and uncoated probes (Fig. 
3.4c and d, coated N=8, uncoated N=6), though a large degree of variance was observed within 
each group. In general, microglial expression was found to be condensed and strongly activated 
immediately next to each probe tip, while activated astroglia were observed occupying a sparse, 
broad field around each probe. 
Significant amounts of tissue were observed clinging to the array following pull out from 
the fixed brain despite thorough post-fixation and careful removal, particularly at the upper 
shank of the electrodes near the array substrate. In one of the two study animals that survived to 
experiment completion, the tissue pull-out was limited to the upper length of the electrode 
shanks, and the tissue at the electrode tips was left intact for preparation and imaging. However, 
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in the second animal tissue was pulled out over the entire length of a majority of the array 
electrodes, making the application of our histology procedure impossible. 
 
 
Figure 3.4: Histology. a-b) 40X confocal microscopy of tissue reaction at representative probe tips for 
coated and uncoated sites, at 11 days post-implant. Green = OX42 (activated microglia), red = GFAP 
(activated astroglia), blue = Hoechst 33342 (nuclei). SB = 100 µm. c-d) Average normalized intensity vs. 
distance from probe centroid for one animal. No significant differences were found between uncoated 
and coated probes (N=6 for uncoated, 8 for coated. Data presented as mean ± SE. p>0.01 for all). 
 
 
3.3.6   Explant Imaging 
 
Scanning electron microscopic images of representative explanted electrodes are shown in figure 
3.5, including uncoated (Fig. 3.5a) and coated (Fig. 3.5b) examples. Uncoated explanted 
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electrodes demonstrated dimensions and surface texture visually consistent with pre-implant 
micrographs. Coated explanted electrodes exhibited intact coatings with no visible cracks, 
spallation, or removal in over 85% of the electrodes examined. Fibrous ingrowth was also 
observed on the surface of the intact coated explanted electrodes, penetrating and occluding the 
open lattice structure of the coating. We were unable to determine the composition of this residue 
due to the preparatory steps performed for high resolution SEM. 
 
 
Figure 3.5: Explant imaging. SEM imaging of representative explanted uncoated (a) and coated (b) 
electrode tips. Tips were cleaned using trypsinization and dried before imaging. SB = 3 µm. 
 
 
 
3.4   DISCUSSION 
 
The goal of this study was to evaluate the in vivo stimulation safety and tissue reactivity of drug-
releasing MWCNT-doped PEDOT coating on platinum/iridium microwire electrodes and to 
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compare the recording performance of these electrodes against those that are uncoated. Uncoated 
platinum/iridium microwire electrodes served as controls for comparison of in vivo performance. 
Uncoated electrodes were employed in place of variations of coated electrodes for several 
reasons: 1) While it is possible to produce MWCNT-doped PEDOT coatings either without any 
drug co-dopant or with an alternative bioactively-inert co-dopant, such a change would 
substantially alter the morphological and electrochemical nature of the resultant coating. This 
may be observed by comparing the morphology of MWCNT and dexamethasone-doped PEDOT 
coatings produced here and MWCNT-doped coatings produced by Luo et al.223 which each 
possess very different surface textures and feature dimensions. Such a coating would be 
unacceptable for use as an appropriate control, as it would introduce many confounding 
characteristics. 2) While uncoated platinum/iridium microelectrodes also exhibit very different 
electrochemical properties, their properties have been very well characterized. They also serve to 
represent the current state-of-the-art microwire electrode. 
We demonstrated the release of dexamethasone from the coating in vitro using a selected 
stimulation method that was not observed to generate an atypical degree of tissue inflammation 
and was not observed to affect neural activity or recording performance. Both coated and 
uncoated probes exhibited a comparable degree of tissue inflammation after 11 days post-
implantation. However, no evidence of dexamethasone activity was observed in vivo, suggesting 
that either the released quantities were too small or too brief to elicit a significant effect, or that 
the effect of release was too subtle to discern using the selected methods. While impedances of 
the coated probes were observed to remain within a range comparable to pre-implanted PBS 
measurements during the initial days post-implantation, values increased rapidly after three or 
four days in vivo and exhibited distinctive high-frequency reactance behavior in Nyquist plots, 
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suggesting some form of probe encapsulation. Nevertheless, the recording performance of the 
coated electrodes was not compromised upon coating or stimulation, suggesting the safety of the 
technology.  
 
3.4.1   Deposition, Morphology, and In Vitro Electrochemical Properties 
 
Preliminary deposition testing was performed using a variety of potentiostatic and galvanostatic 
electropolymerization methods with final parameters being selected to maximize coating 
uniformity, robustness, and impedance reduction. We found that electrodeposition using constant 
potential produced the most consistent coatings in terms of uniformity and surface morphology 
on both gold macroelectrodes and Pt/Ir microelectrodes. This is in contrast with observations by 
Zhou et al.205 who found that constant current polymerization resulted in better 
PEDOT/MWCNT films. Interestingly, our method produced the open nanofibrous lattice-like 
morphology exhibited in figures 3.1a and b, which is similar to the PEDOT/CNT films without 
Dex that we previously reported223, while films produced by Zhou et al. exhibited a more 
cauliflower-like morphology205. A possible explanation is that our CNT size range and 
functionalization method may have resulted in a greater fraction of entrapped nanotubes, or a 
different rate of PEDOT deposition. Parameters were individually optimized for each type of 
electrode to provide the most similar impedance performance and morphology. A relatively high 
1.3 V (vs. Ag/AgCl) was employed to coat Pt/Ir microelectrodes as lower potentials resulted in 
poor and inconsistent impedance reduction. Coating deposition on Pt/Ir was carried out to a 
charge density of approximately 0.29 C/cm2. It was observed that careful and precise MWCNT 
functionalization and suspension preparation were critical to achieving consistent and robust 
coating deposition between samples.  
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SEM imaging of the dex/MWCNT/PEDOT coating revealed an open and extremely 
porous lattice morphology (Fig. 3.1a-b) comparable to that observed by Gerwig et al.208 who 
prepared similar PSS/SWCNT/PEDOT coatings on gold MEAs. High resolution imaging at 
various stages of the film synthesis suggests that this morphology was achieved through the 
partial entrapment of CNTs within the growing PEDOT, after which the exposed lengths of the 
tubes were overgrown and encapsulated to form long interconnected fibrils. Progressive CNT 
entrapment and encapsulation continued until the coating attained the thick “bird nest” 
appearance visible in the SEM images. Typical fibrils possessed diameters over 70nm greater 
than that of the MWCNTs supporting them, suggesting the presence of a uniform and continuous 
encapsulating film of PEDOT. Despite the fragile appearance of the coating, preliminary 
qualitative testing revealed that coated electrodes were able to be inserted and removed from pia 
and cortical tissue with no visible change to the coating surface appearance or dimensions, 
indicating adequate mechanical resilience of the coating lattice and adhesion to the metal 
substrate. Despite the lack of covalent bonding between the PEDOT and metal, coating 
adherence was observed to be excellent. The high surface roughness of the substrate apparent in 
figure 3.1c, which resulted from the plasma arc method used by the manufacturer to expose the 
electrode tips, may have had a positive effect on adhesion. Adhesion may have also been 
enhanced by the added structural benefits provided by the MWCNT component. Comparative 
SEM imaging between the coating on gold macroelectrodes and on Pt/Ir microelectrode tips 
demonstrated no apparent difference in surface morphology or feature size. 
Coated microelectrodes exhibited a significant decrease in 1 kHz impedance and an 
increase in cathodic charge capacity, which were observed by other studies using similar 
compositions208,220. This impedance decrease and charge capacity increase is a hallmark of 
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conducting polymer coatings on electrodes191,224 and is the product of multiple factors including 
the high conductivity of the oxidized PEDOT and MWCNT components, the large double layer 
capacitance produced by the greatly enhanced electrode/electrolyte interface surface area, and 
the charge transfer mechanisms available at the PEDOT interface due to redox activity and ion 
diffusion. Our coatings demonstrated a 1 kHz impedance decrease of ~40%, which was 
significant but was substantially less than that observed by Gerwig et al.208 who reported 
reductions of over 95% following PSS/SWCNT/PEDOT coating on gold MEA sites. This 
contrast in performance is likely a consequence of both the poor doping capability of 
dexamethasone compared to PSS which led to reduced PEDOT conductivity, as well as the 
heightened initial uncoated impedance per unit surface area of gold planar electrode sites 
compared the rough Pt/Ir microwire tips.   
 
3.4.2   Stimulated Release 
 
A challenge faced within this study was the development of a release stimulus that would 
generate effective local concentrations of drug without leading to tissue damage, hydrolysis, or 
electrode corrosion65,68. The release of anionic dopant from a conducting polymer requires a 
negative voltage with magnitude large enough to surpass the polymer’s reduction potential, with 
the release quantity increasing as more negative potentials and greater stimulus durations are 
applied186. While constant DC or square wave stimulus may yield good release performance, 
they also produce a condition of charge imbalance which may lead to both tissue injury as well 
as electrode instability65. Alternatively, sinusoidal or triangular AC waveforms limit dwell time 
at potentials below the reduction potential. Despite their safety advantage, the AC waveforms 
also increase the complexity of release dynamics due to electrostatic attraction and polymer re-
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doping with released drug, thus reducing the effective yield. While waveforms intended for 
functional stimulation are typically balanced to prevent charge buildup, such balancing is 
difficult to achieve in waveforms intended for drug release, which are usually potential-
controlled to ensure consistent reduction, and of a lower frequency to both increase dwell time 
below the reduction potential as well as to increase the extent of drug diffusion into tissue before 
the subsequent cathodic pulse. 
Within this study we used a conservative stimulation paradigm, cyclic voltammetry (CV), 
which approximates charge balanced conditions while providing information on both redox 
behavior and charge storage capacity. CV has been successfully employed as a release 
stimulation in vitro in several prior studies184,187,189 though with much slower scan rates of 20-
100 mV/s compared to the 1 V/s rate used here. We considered these slow scan rates to be 
unfeasible in vivo due to the increased anesthesia time required, as well as increased unbalanced 
charge buildup. It is understood that despite the 80%-90% charge balance observed, significant 
surplus charge will still be generated, particularly if a slow scan rate is used. Also, the 
requirement that the stimulus pass below the -0.7 V (vs. Pt/Ir) PEDOT reduction potential for 
release leads to a violation of the water window68 and the possible evolution of hydrogen gas 
through hydrolysis, though the maximum voltage that may be applied without creating an unsafe 
interfacial potential drop is difficult to predict, due to the in vivo environment and the potential-
controlled nature of the stimulation. A fast CV scan minimizes the time spent at potentials that 
may result in permanent damage of the electrode tissue interface. PEDOT reduction and ion 
transfer were verified by way of the observation of a reduction peak during release stimulation in 
all coated channels daily throughout the experiment. This peak confirms that dexamethasone was 
released, though the duration of release could not be determined as the coating likely re-doped 
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itself with local ionic species as the dexamethasone content was depleted. Material stability 
following stimulation was verified using SEM imaging of electrode surfaces, and it was found 
that the morphology remained visually unchanged after 200 cycles. Tissue integrity was 
monitored using both post-stimulation impedance measurement as well as histology, which did 
not reveal obvious evidence of stimulation-induced lesion or a harmful degree of gas evolution. 
CV scans also revealed consistent redox behavior and charge storage characteristics throughout 
the experiment duration. These evidences suggest that the majority of charge was transduced by 
way of safe, reversible mechanisms, and that the stimulus did not generate an observable degree 
of hydrolysis. 
Despite the surface area enhancement provided by the MWCNT dopant, dexamethasone 
release trials using coated gold macroelectrodes revealed that stimulated-release quantities 
remained barely detectable using absorption spectroscopy, resulting in a significant increase only 
being detectable after ten cumulative stimulation sets of 20 CV cycles each (-0.9 V to 0.6 V, 1 
V/s). Our observed 2.06 μg/cm2 stimulated release quantity only represented a 31% increase over 
passive release. A comparable dexamethasone release study by Wadhwa et al.184 using 
polypyrrole demonstrated a stimulated release of ~10 μg/cm2 after a single set of 20 CV cycles (-
0.8 V to 1.4 V, 100 mV/s). This illustrates that even with MWCNT enhancement the much lower 
dopant capacity of PEDOT requires a more aggressive stimulation protocol to release a drug 
quantity comparable to polypyrrole films. Both our coating and the coating studied by Wadhwa 
et al. were shown to passively release roughly equivalent amounts of dexamethasone during the 
same amount of time. The difference in release capacity between our earlier polypyrrole studies 
and the current PEDOT-based coating study may be the result of a number of factors, including 
the differences in film electrochemical properties and the more aggressive stimulation protocols 
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used within earlier studies. A preliminary trial using a more aggressive release protocol (-2.0 V 
to 0 V 10 s square wave) yielded over double the quantity of released drug compared to the CV 
stimulation method used in vivo. However, this more aggressive method is both highly charge 
imbalanced and also subjects the environment to unsafe potentials for extended time periods, 
which would likely generate irreversible damage to both tissue and electrode. It is also worth 
pointing out that this study was focused on neural recording applications, which excluded 
stimulation parameters that may cause changes in neural activity patterns. 
As our coating method produced visually identical film morphologies on both gold 
macroelectrodes and Pt/Ir microwire tips, we employed release quantities from macroelectrodes 
to estimate release from coated microwires in vivo. Scaling the macroelectrode release quantity 
by the microwire coating surface area and dividing by ten to determine release for a single set of 
cycles yields a daily release quantity of 0.21 µg/cm2, which equates to an estimated average 
tissue dexamethasone concentration of 0.42 µM within a 500 µm radius from the implanted 
microwire tip. In comparison, Zhong et al.127 observed 0.18 µg/cm2 dexamethasone release from 
slow release coatings in 24 h, yielding a local concentration of 0.36 µM. As an effect on glial 
inflammation has been observed225 following an introduction of dexamethasone concentrations 
as low as 0.2 µM in vivo, evidence suggests that our release method produced physiologically 
relevant dexamethasone concentrations in local tissue. 
 
3.4.3   In Vivo Electrochemical Properties 
 
The dex/MWCNT/PEDOT-coated probes demonstrated dynamic multimodal changes in in vivo 
broad-spectrum impedance over the eleven day period of implantation, which suggests a 
progression of changes to physiological or material factors at the tissue/coating interface. This is 
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contrasted against the behavior of uncoated probes, which exhibited a gradual increase in 1 kHz 
impedance typical of chronically implanted uncoated microelectrodes during the first week post-
implantation in rat cortex10,21,203. This distinction between the chronic impedance behavior of 
PEDOT-coated and uncoated implanted electrodes was first noted by Abidian et al.203 who 
observed complex changes to Nyquist representations of PEDOT nanotube-coated electrode sites 
which were not evident in uncoated controls, and coincided with a sharp increase in 1 kHz 
impedance during the initial 2-week period post-implantation. This increase in 1 kHz impedance 
has since been observed by others studying the in vivo performance of PEDOT-coated 
electrodes204,206. We observed similar phenomena in our Nyquist plots, suggesting that these 
progressive changes to impedance behavior may be common to PEDOT-coated electrodes in 
vivo. However, while the 1 kHz impedance of PEDOT-coated sites within Abidian et al.’s work 
remained significantly lower than uncoated sites over the duration of the experiment, the average 
impedance of coated electrodes in our work increased to the point where it became statistically 
indistinguishable from that of uncoated electrodes within five days of implantation. This is 
possibly due to the contrast in initial impedances, as Abidian et al. observed a 90% reduction 
between day 0 PEDOT-coated and uncoated site impedances, compared to the 40% reduction 
seen in our own. 
 
3.4.4   Neurophysiological Recording 
 
For this study we elected to use the visual cortex model due to the simplicity of stimulation as 
well as the surgical accessibility of the cortical region, which was attractive due to the large 
profile of the FMA implant. The visual cortex lacks the curvature and dense surface 
vascularization of barrel cortex, and the comparative lack of columnar structures in rat V1226 
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should conceptually lead to more uniform and homogenous neural activity across all array sites 
with proper stimulation. The Long Evans rat was selected as our model strain due to their 
excellent visual acuity227.  
Both spontaneous and evoked neural activity was recorded before and after daily release 
stimulation and impedance measurement. A variety of different visual stimulation programs were 
applied to the subject each session, though for the purposes of this study all measures were 
averaged together across spontaneous and evoked blocks. In order to provide an assessment of 
raw recording performance, metrics of signal-to-noise ratio, noise amplitude, and LFP amplitude 
were quantified. In general, only sparse unit activity was observed across both coated and 
uncoated probes over the initial week of implantation, though both coated and uncoated probes 
exhibited well-defined units. Activity in both coated and uncoated probes increased substantially 
within recordings taken during the final days of implantation, with recording quality being 
essentially equivalent. As probe impedance was also observed to be equivalent between coated 
and uncoated probes at those time periods, this result was expected. The inconsistent probe 
performance during the initial week post-implantation as well as the subsequent increase in 
performance has been observed previously38 and is thought to correspond with the progression of 
acute inflammation and edema local to the implanted electrodes and the eventual stabilization of 
the interface tissue as it enters the chronic inflammatory stage. 
 
3.4.5   Histology 
 
Subjects were perfused for tissue histology at day 11 post implantation. This implantation 
duration was selected to allow for the observation of the transition of the interfacial inflammation 
as it progressed from the acute to the chronic state. While a longer experimental duration would 
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have been preferred for the assessment of recording performance, we decided that the 11 day 
time point would provide a compromise between recording assessment and the potential to 
observe the effects of released dexamethasone within the tissue, which we expected to be most 
pronounced during the initial acute inflammatory response. Systemic221 and local127 
dexamethasone introduction to chronically implanted probes has been observed to elicit a subtle 
effect on observed tissue inflammation, with effects diminishing for most markers after the 
administration of dexamethasone is ceased. Both studies reported significantly reduced astrocytic 
activation following dexamethasone administration, quantified using the marker GFAP. 
However, microglial response was observed to be less consistent, with systemic dexamethasone 
administration yielding either no effect or enhanced microglial activation, and local 
administration yielding a decrease in microglial activation that did not persist to a more chronic 
time point. As the quantity of introduced dexamethasone from the stimulated release of our 
coating was expected to be comparable to that introduced through a slow-release coating, it was 
thought that evidence of release may only be apparent within the initial acute time period. 
However, our histology revealed no significant difference between either astroglial or microglial 
response in the vicinity of the coated and uncoated electrode tips, suggesting that either the 
actual release quantity was substantially lower than that estimated from macroelectrode release, 
that the dexamethasone yield of the film was expended at a time point too early to produce a 
visible effect at day 11, or that the effect of the released drug on local tissue response was too 
subtle to be quantified using our methods. The similarity of the observed tissue response around 
coated and uncoated electrodes also suggests that the release stimulation method did not generate 
tissue damage, considering that the coated electrodes injected over three times the amount of 
charge as uncoated electrodes daily throughout the experiment. It is thus assumed that the 
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additional charge delivered through the coated electrodes was transduced via safe mechanisms 
such as coating reduction and dopant release. It should be noted that this conclusion is drawn 
from a limited sample size, as the tissue from only one animal was available for quantification 
due to extensive tissue pullout in the second animal. Also limiting our histology was the fact that 
only a few sections were available for examination from each probe due to the very small size of 
the coated microwire tips, each being approximately 30 µm long. 
 
3.4.6   Potential Applications 
 
The observations collected here suggest that variations to this type of drug-release coating could 
provide the platform for the development of a variety of release systems incorporating a large 
assortment of bioactive agents. The coatings are simple to synthesize and can be 
electrochemically applied to most commercial bioelectrode designs for recording or stimulation, 
including both cortical and peripheral electrodes as well as cardiac pacemakers. The technology 
offers the ability to release discrete amounts of drug at a very fine temporal resolution on 
command using a safe electrical stimulus, allowing for the release of anti-inflammatory and/or 
neuroprotective agents upon detection of a biochemical trigger within the local tissue, or the 
simultaneous release of neuromodulatory agents while recording neural activity in vivo. These 
capabilities could allow this technology to substantially inform future biopotential electrode 
design, as they provide a simple, inexpensive, minimal-profile tool for modulating the tissue 
environment to a precisely controllable degree. Such designs could be used to neurochemically 
probe discrete neural pathways in vivo, or to develop the next generation of minimally-invasive 
cortical interface, bringing the technology closer to widespread clinical use. 
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3.5   CONCLUSION 
 
We demonstrate that the dexamethasone and MWCNT-doped PEDOT coating is capable of 
release of drug in vivo, confirmed by way of the observation of coating reduction behavior 
during cyclic voltammetry. We further demonstrate that daily CV stimulation with parameters 
selected for drug release and applied to uncoated and PEDOT-coated intracortical electrodes do 
not generate substantial acute changes to 1 kHz impedance or local neural activity, and do not 
incite inflammatory tissue response at 11 days post-implantation atypical from that observed 
around similar unstimulated electrodes elsewhere207. Moreover, the acute impedance, recording 
performance, and degree of tissue reactivity between uncoated and coated probes was observed 
to be statistically indistinguishable despite the fact that release stimulus applied to coated 
electrodes injected approximately three to four times the quantity of charge injected by way of 
uncoated electrodes. However, quantities of drug released during the stimulation of PEDOT was 
observed to be substantially lower than that released from comparable polypyrrole coatings, even 
when the PEDOT effective surface area was enhanced using a MWCNT co-dopant. It is 
theorized that the low release is largely due to the more conservative stimulation protocol 
employed to limit potential tissue damage. We conclude that the 
PEDOT/MWCNT/dexamethasone coating remained morphologically stable for the duration of 
implantation and daily stimulation, as evidenced by a consistent level of charge storage capacity 
as well as a lack of observed physical damage in explant imaging. The release stimulation was 
determined to be safe on the basis of observed inflammatory tissue response as well as the lack 
of immediate changes to impedance and neural activity following stimulation. The coating was 
not observed to hinder neural recording, and performed comparably with uncoated electrodes. 
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4.0   CIRCUIT MODELING OF IN VIVO DEXAMETHASONE/MWCNT/PEDOT-COATED 
ELECTRODES 
 
 
4.1   INTRODUCTION 
 
Electrical impedance is a measure of the restriction to the passage of current within a circuit 
upon the application of a voltage, and is analogous to electrical resistance applied to an 
alternating current. Unlike direct current resistance, impedance is represented by both a 
magnitude as well as a phase angle, representing the phase shift of capacitive or inductive 
elements within the circuit that are reactive to changing frequency. Electrical impedance 
spectroscopy (EIS) is a technique which allows for the measurement of changes to impedance 
magnitude and phase across a range of frequencies, and can be used to evaluate the electrical 
characteristics of an electrode/electrolyte interface. Within a properly designed electrochemical 
cell it is possible to isolate the impedance characteristics of a working interface from the rest of 
the measurement circuit, allowing for the detailed analysis of specific components within the 
interface such as electrode and coating capacitances, charge transfer resistances, diffusion 
characteristics, and others228. The frequency range employed is dependent on the interface 
features of interest (Fig. 4.1), with typical ranges being between 1 Hz and 100 kHz. For each 
measurement, a sinusoidal voltage or current is applied at a select frequency with magnitude 
small enough that a linear current-voltage response is maintained68. Potentiostatic EIS is 
typically preferred as it allows for the fine control of the current flowing through the circuit 
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during measurement21. EIS has been found to be quite useful in assessing the electrochemical 
properties of microelectrodes, and may be safely applied in vivo due to the small voltage 
excursion magnitudes68. 
 
 
Figure 4.1:  Dominant effects on bioelectrode impedance by frequency range (From Karp et al,229 ©2007 
IEEE. Reprinted with permission). 
 
  
EIS has been applied to a broad range of biological tissues230 and has been used to 
characterize neural recording electrode properties for over forty years69. In particular, impedance 
measurement has been used to study and quantify tissue response around chronically implanted 
electrodes, initially in the loins of cats231 and later within the cortices of rats15,21,38,41,232,233. 
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Williams et al. demonstrated that implanted electrode impedance is somewhat correlated with 
inflammatory reaction intensity41, and Prasad et al. employed chronic impedance data to develop 
a predictive model for electrode failure likelihood21. However, the particular cellular and 
extracellular elements that contribute to these impedance changes are thought to be multifaceted 
and complex76,234. 
 Early work concentrated on the increased tortuosity λ of astrogliotic scar, defined as 
𝜆 ≡ (𝐷 𝐷∗⁄ )1 2⁄  where D is the diffusion coefficient of water and D* is the diffusion coefficient of 
the barrier material, as determined by the diffusion of tetramethylammonium through cortical 
stab scar tissue65,93. Subsequent studies attempted to isolate the impedance contributions of 
various elements of the inflammatory tissue response, cellular and proteinaceous, both in 
vitro183,229,235,236 and in vivo76,234. A principal tool of many of these studies is the equivalent 
circuit model, or a mathematical representation of the electrode/environment interface as a 
circuit composed of various elements selected to approximate the behavior of the known 
components of the interface (Fig. 4.2). Such elements may include capacitors to represent 
double-layer interfaces and resistors to represent charge-transfer resistances or bulk electrolyte 
conductivity. 
 A large assortment of equivalent circuit models have been developed with varying 
degrees of sophistication, intended to represent electrode interfaces of complexity ranging from 
simple bare metal electrodes in saline, to coated electrodes surrounded by reactive tissue in vivo 
(A review by L. A. Geddes discusses the historical development of equivalent circuits as far back 
as the late 1800s237). A sampling of different interfacial equivalent circuits employed by 
microelectrode implantation and coating studies is shown in figure 4.3. Circuits are typically 
selected to balance fit quality against parameter ambiguity, as simple circuits may not be able to 
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fit complex spectra effectively, while overly sophisticated circuits may not fit individual 
elements with confidence due to overlap. Another important consideration during model 
selection is the frequency range available for fitting, as many interfacial impedance mechanisms 
will only dominate within specific domains. 
 
 
Figure 4.2:  An example equivalent circuit, the “lumped element” model. Note representations of 
electrode surface, glial membrane, and extracellular space. Am is a scaling factor for glial density. CPE is a 
constant phase element. (From Johnson et al,232 ©2005 IEEE. Reprinted with permission). 
 
 
Figure 4.2 and many models within figure 4.3 incorporate an element known as the 
constant phase element (CPE)238,239. The CPE is a mathematical entity defined as: 
𝑍𝐶𝑃𝐸 = 1(𝑗𝜔)𝛼𝑄 (4.1) 
where ω is angular frequency in rad/s, α is a dimensionless CPE exponential term from 0 to 1, 
and Q is the CPE coefficient with units sα/Ωcm2. The CPE was developed to model data with 
behavior suggesting a non-ideal capacitor, with α representing the deviation of phase angle (with 
α = 1 representing a phase angle of 90° and thus ideal capacitive behavior, and α = 0.5 
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representing phase angle 45° and thus 50% resistive character. As many real systems exhibit 
peak phase angles well below 90°, the CPE is able to fit this data much more effectively than an 
ideal capacitor240. While the physical and electrochemical factors that cause this non-idea 
behavior are not well understood, evidence suggests them to be a combination of surface 
roughness and inhomogeneity, porosity, and non-uniform current distribution over the electrode 
surface, as reviewed by Jorcin et al. in 2006240. 
The simplest circuit representation of the interface between a metal electrode and 
electrolyte is that of a capacitor in series with a resistor.  This capacitor is typically known as the 
double layer capacitance, as discussed in chapter 1.2, and is a consequence of charge buildup 
within the electrolyte local to the electrode surface. This simple series circuit model is generally 
only appropriate for representing a theoretical “perfectly blocking” interface, and offers no 
leakage current route bypassing the capacitor. As no faradaic current mechanism is included, the 
model will act as an open circuit in DC conditions. Substituting a CPE for the capacitor within 
this model (Fig. 4.3a) provides more flexibility, and may be applied to systems demonstrating 
linear and constant phase behavior, such as blocking metal electrode systems in electrolyte at 
intermediate (100 Hz to 10 kHz) frequency ranges where diffusion limitations to ionic motion do 
not play a role241. This model was originally developed by Warburg in 1899237, who limited α to 
0.5 (Subsequently, a CPE with phase angle 45° is commonly known as a Warburg impedance 
element). In 1932, Fricke adapted this model by recognizing that α can be observed to vary 
substantially from 0.5 depending on the metal employed237. 
Placing a resistor in parallel with the CPE of the Fricke model provides a leakage current 
pathway bypassing the double-layer capacitance (Fig. 4.3b), and represents the resistance to 
charge transfer across the interface in DC conditions. This resistance is a summation of three 
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different mechanisms (Fig. 4.3c) as discussed by Dymond in 1976242, where RT is the resistance 
to faradaic charge transfer, ZD is the impedance to ionic diffusion at the interface (which can play 
a role in faradaic reaction mechanisms with rapid kinetics), and ZR is the reaction impedance, 
which represents the contribution of slow rate-limiting steps of the faradaic reaction. Note that 
ZD and ZR are frequency dependent. This parallel capacitance/resistance element is commonly 
known as a Randles element, and it serves as the conceptual foundation for many more 
sophisticated models237. 
Both the Fricke and Randles elements are commonly modified through the incorporation 
of a diffusion impedance element to account for mass transport (Fig. 4.3d and e, respectively). 
This is often represented by a Warburg element, though the Warburg element is occasionally 
modified to allow deviation from 45° constant phase behavior at certain frequency ranges, as 
discussed by Bobacka et al.243 and Gerwig et al.208. This diffusion impedance typically only 
dominates at very low frequencies where capacitive transduction is not available, and thus may 
be ignored at the more intermediate ranges (>1 Hz) typically employed in in vivo 
measurement244. 
Figure 4.3f demonstrates a more sophisticated model featuring two independent 
capacitive interfaces, represented by two Randles elements in serial (with one incorporating a 
diffusion impedance element). Models such as this are typically used in the case of encapsulating 
barriers surrounding an inner electrode, where current must cross one interface and then the 
other245. Models shown in figures 4.3g and h take a different approach and feature nested 
Randles elements, often used in evaluation of thin film coatings where current is not forced to 
traverse both capacitive boundaries, with charge instead building up on either the coating surface 
or the inner electrode surface following the traversal of a pore resistance (Rl or RPore within the  
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figures). Another alternative is the “lumped element” model shown in figure 4.2, which attempts 
to model the interface based on known electrophysiological parameters such as cell membrane 
capacitance, amplified using a scaling factor to represent cellular density41. Note that each model 
incorporates a serial resistive element, typically RS, which represents the bulk resistance of the 
electrolyte. Measurements have shown that bulk cortical tissue acts as a pure ohmic medium and 
does not exhibit frequency-filtering characteristics, allowing it to be modeled as a single 
resistor246. 
 
 
 
 
Figure 4.3: Example equivalent circuits used in microelectrode characterization.  a) Fricke model241.  b) 
Randles model241.  c) Randles model demonstrating faradaic impedance components. RT = charge 
transfer resistance, ZD = diffusion impedance, ZR = reaction impedance242.  d) Fricke model with diffusion 
impedance243.  e) Randles element with diffusion impedance208.  f) Double serial Randles model with 
diffusion impedance element on the inner interface245.  g) Nested Randles element for thin film 
coatings247.  h) Nested Randles element with diffusion impedance element within inner interface202. 
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 Impedance data shown in this chapter will be presented in Nyquist plots. Nyquist plots, 
also known as Cole-Cole plots, are used to exhibit data on a complex impedance plane, with the 
abscissa representing the real component of impedance, or the resistance, and the ordinate 
representing the imaginary component of impedance, or the reactance. Each point in the plot is 
representative of a single frequency of measured data, with the resistance and reactance at that 
point indicative of the degree the impedance modulus is dominated by the resistive or the 
capacitive elements of the interface. An example Nyquist plot is shown in figure 4.4, and 
demonstrates the anticipated plot shapes of various interfacial components, including tissue and 
electrode as well as a combined plot similar to what would be observed in typical in vivo 
measurement from 100 Hz to 10 kHz (high frequency points being at the lower left within the 
plot). Note the linear appearance of the electrode plot, indicating simple CPE behavior. Tissue 
response typically exhibits itself as a bump of increased reactance at high frequencies, 
representing a second capacitive interface with its own associated time constant41. 
This dissertation chapter describes the adaptation of an equivalent circuit model to better 
interpret the chronic in vivo impedance data collected from bare Pt/Ir and 
dexamethasone/MWCNT/PEDOT-coated electrodes in chapter 3 of this dissertation. A number 
of simple models were initially evaluated and found to result in poor fitting performance. 
Instead, we looked to an alternative model, henceforth referred to as the Bisquert model. The 
Bisquert model was first described by Bisquert et al. in 2000248 as an improvement over existing 
dual-channel transmission line interface models, and incorporated the means to evaluate 
microscopic dispersive processes across porous surfaces. The use of transmission line theory in 
place of discrete circuit elements allows the model to evaluate distributed properties across 
defined diffusion lengths. The model was initially employed to study TiO2 nanoporous film 
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electrodes249 and later thiophene-based conducting polymers248. It has since been adopted within 
several microelectrode studies, including the evaluation of impedance changes of implanted 
cochlear electrodes250, and the impedance properties of SWCNT-doped polypyrrole220 and 
MWCNT-doped PEDOT in vitro205. 
 
 
Figure 4.4:  Illustration of Nyquist plots of electrode and tissue behavior.  
 
 
 
4.2   METHODS 
 
4.2.1   Model Derivation 
 
An in-depth treatment of the derivation of the Bisquert model can be found in Bisquert et al. 
(2000)248, and is summarized here. As stated above, this model is a dual-channel transmission 
line model which simplifies the complex interfacial characteristics into a superposition of 
“conducting solid” and “electrolyte” continua. Through this simplification, the current flux 
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between the solid and solution phases are explored. Similar to the Randles model above, the two 
principle mechanisms which enable this flux coupling are electrochemical charge-transfer 
processes and conducting solid polarization due to interfacial charge buildup. However, due to 
the electrochemical complexity of the conducting polymer, it is theorized that a model 
incorporating spatially distributed processes will provide more realistic information than a model 
featuring a simple macroscopic non-distributed resistance such as the Randles circuit. A general 
expression of the impedance of a dual-channel transmission line is given by: 
𝑍 = 𝜒𝐿𝜒𝑆
𝜒𝐿 + 𝜒𝑆  �𝐿 + 2𝜆sinh�𝐿 𝜆� �� + 𝜆 𝜒𝐿2 + 𝜒𝑆2𝜒𝐿 + 𝜒𝑆 coth�𝐿 𝜆� � (4.2) 
where L is the layer thickness and 𝜆 =  [𝜁/(𝜒𝐿  + 𝜒𝑆)]. The elements χL and χS represent the 
impedance per unit length (Ω m-1) of the solid and liquid phases respectively, and are typically 
dominated by either conductivity or mass transport properties within the medium. The element ζ 
represents the impedance per unit length of the exchange of charge at the solid/liquid interface, 
and in effect is a summation of capacitive and faradaic mechanisms at that interface. 
 Bisquert et al.248 optimized this general transmission line model for conducting polymer 
coating applications through a number of key simplifications and assumptions. In theory, the 
general model may be adapted to a wide variety of interfacial conditions through modifications 
to the element ζ. For example, in the case of a perfectly polarizing interface between the solid 
and liquid phases, ζ would be represented as the impedance of an ideal capacitor, or: 
𝜁 = 1
𝑗𝐶𝜔
 (4.3) 
where C is interfacial capacitance and ω is angular frequency. In place of this, Bisquert modeled 
the interface as a non-ideal capacitor (represented as a CPE) and a charge transfer resistance: 
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𝜁 = 𝑟01 + 𝑟0𝑞0(𝑗𝜔)𝛽 (4.4) 
where r0 is the charge transfer resistance per unit length, q0 is the CPE capacitance coefficient, 
and β is the CPE exponential factor. This adaptation allows for the evaluation of a number of key 
charge exchange mechanisms248. 
 To greatly simplify the mathematics of the model, Bisquert et al.248 assumed the 
resistivity of the solid phase to be minimal compared to the contributions of the other interfacial 
components and set χS to be 0, essentially eliminating the first half of the general model. This 
assumption requires both that the conducting polymer remain in a highly conductive oxidized 
state, and that this conductivity be uniform throughout the thickness of the coating. While this 
assumption is justifiable in the case of conducting polymer coatings, it may not carry over to 
other types of conducting solids as effectively, such as glial scar tissue. In addition, Bisquert et 
al.248 simplified the expression of ionic transport resistance within the fluid phase to be uniform 
and ohmic, represented as χL = rL. For fitting purposes, L is set equal to 1. 
 With these assumptions and the new definition of ζ taken into account, the general 
expression (4.2) is transformed into a more specific expression of interfacial impedance, or: 
𝑍 =
⎣
⎢
⎢
⎢
⎢
⎡
𝑅𝐿𝑅01 + �𝑗𝜔 𝜔0� �𝛽
⎦
⎥
⎥
⎥
⎥
⎤
1
2�
coth��𝜔0 𝜔𝐿� �1 2� �1 + �𝑗𝜔 𝜔0� �𝛽�1 2� � (4.5) 
where ω is angular frequency, RL and R0 are the total liquid phase and charge transfer resistance 
values across the coating thickness (RL = rLL and R0 = r0/L), and ω0 and ωL are the characteristic 
frequencies of the charge transfer process and of the ionic diffusion through the layer, defined as: 
98 
 
𝜔0 = 1(𝑟0𝑞0)1 𝛽�  = 1(𝑅0𝑄0)1 𝛽�  (4.6) 
𝜔𝐿 = 1(𝑟𝐿𝑞0𝐿2)1 𝛽� = 1(𝑅𝐿𝑄0)1 𝛽�  (4.7) 
where Q0 is the total CPE coefficient across the coating thickness (Q0 = q0L) with units F sβ-1. 
While (4.5) is a simplified expression intended purely to explore the charge exchange dynamics 
of the interface, most of the weaknesses of the model, including the simplification of faradaic 
processes and DC behavior at the metal interface as well as the assumption of fluid phase 
resistive uniformity, may be neglected at intermediate frequency ranges248. A diagram of the 
Bisquert model and representative complex plots are shown in figure 4.5. 
 
 
Figure 4.5:  The Bisquert diffusion impedance model. a) Diagram of the transmission line representation.  
b) Example complex plots demonstrating model behavior in Nyquist space. R3 curve represents charge 
transfer resistance. (Plots from Bisquert et al.248 © Elsevier, Reprinted with permission). 
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4.2.2   Data Fitting 
 
The Bisquert model was selected to serve as a combination representation of the 
dex/MWCNT/PEDOT conducting polymer coating as well as the surrounding tissue response, as 
a component of a wider model including metal electrode and electrolyte parameters. This model 
(Model A) is shown in figure 4.6a, with ZD representing the Bisquert impedance, CCPE 
representing the metal surface CPE coefficient, α representing the exponential term of CCPE, RCT 
representing the charge transfer resistance of the metal interface, and RSER representing the serial 
resistance of the bulk electrolyte/brain. A second model, Model B (fig. 4.6b), is identical to 
Model A only lacking the Bisquert impedance, and is intended for uncoated electrodes in PBS or 
at early time points in vivo when a diffusion barrier is not observed within the data. 
 
 
Figure 4.6:  Equivalent circuit models used within this study. 
 
 
Each model was mathematically expressed within a complex non-linear least-squares 
fitting program (MEISP v3.0, Kumho, Seoul, South Korea). Impedance data from daily in vivo 
measurement (as described in chapter 3.2.8) was loaded into the program. Before fitting, the 
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thirteen lowest frequency impedance measurements from each impedance spectrum were 
removed to eliminate scatter due to low-frequency noise, which was found to be a consequence 
of the multisine measurement method. Also, impedance spectra that were found to contain 
enough broadband noise or measurement artifact to interfere with consistent fitting were 
removed. Fitting was typically performed in stages, with an initial fit performed across all data 
sets to observe general trends and identify outliers, and subsequent fits performed employing 
optimized seed values to increase consistency between points. 
 
4.2.3   In Vitro Array Impedance Fitting 
 
To compare and contrast against the in vivo data collected in the previous chapter, impedance 
measurement was performed from identical electrodes immersed continuously in a PBS bath and 
then fit to the model described in section 4.2.2 above. Ten parylene-C insulated Pt/Ir 
microelectrodes (Microprobes for Life Science) identical in nature and impedance range to those 
within the in vivo-implanted FMAs were coated with MWCNT and dexamethasone-doped 
PEDOT in an identical manner to that employed in section 3.2.3. Impedance was measured 
before and after the coating process using the method described in section 3.2.3. Following 
coating, electrodes were soaked in PBS overnight to wash off residual monomer, and then 
mounted within a sealed chamber which continuously immersed the electrode tips in an ambient 
temperature PBS bath while simultaneously allowing their connection to a potentiostat. Once 
daily, 5 of the 10 electrodes were subjected to the same impedance measurement-CV 
stimulation-impedance measurement protocol that was applied to the in vivo FMAs described in 
section 3.2.8. The other 5 electrodes only received daily impedance measurement with no CV 
stimulation. Measurement continued for 11 days, mimicking the in vivo experimental protocol. 
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Collected data were fit using model A described in 4.2.2 above, using the Bisquert diffusion 
impedance element. 
 
 
4.3   RESULTS AND DISCUSSION 
 
4.3.1   Complex Impedance Characteristics 
 
Representative Nyquist plots of recorded impedance data from both uncoated and 
dex/MWCNT/PEDOT-coated electrodes at various time points are shown in figure 4.7. Very 
different features are exhibited by each, in particular on days 7 and 10 when 1 kHz impedance 
was statistically identical. The contrast between uncoated and coated probes on day 1 post-
implantation is evident, with coated probes exhibiting reactance values over an order of 
magnitude lower than uncoated probes, suggesting a greatly increased CPE coefficient and thus 
greatly increased electrode surface area. Also evident in the day 1 Nyquist plot of the coated 
probe is a small high-frequency encapsulation element, likely due to the presence of the coating. 
Uncoated probes exhibit subtle changes to plot slope, curvature, and high-frequency diffusion 
behavior, suggesting that the impedance changes are the result of small changes to the electrode 
surface area, roughness, current uniformity, and ionic diffusion due to the surrounding tissue 
response. In contrast, coated probes exhibit the development of a large high-frequency 
encapsulation element that soon dominates impedance behavior over the majority of frequency 
points. Equivalent circuit analysis was applied to this data, in an attempt to tease out the specific 
physical and physiological correlates to best determine the root of these changes in electrical 
behavior. 
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 Figure 4.7:  Nyquist plots of in vivo data. Representative uncoated (a-c) and coated (d-f) electrode 
impedance behavior. Black points are individual measured frequencies, with colored lines added for 
visibility. 
 
 
4.3.2   Equivalent Circuit Fitting 
 
Multiple trends were observed in the fitted model parameters, as shown in figure 4.8. Confidence 
in the modeled values is to a large part determined by the range of frequencies available for 
fitting, which in this study was limited to minimize the time required for measurement due to 
animal safety concerns. Parameters that are not well represented within the measured frequency 
range may vary substantially without changing the quality of the overall fit. The model 
parameter representing platinum charge transfer resistance, RCT, is an example, as it is most 
relevant to frequencies much lower than those measured here (f < 1 Hz). Parameters 
demonstrating the most dynamic and consistent behavior in coated electrodes were found to be 
CCPE and Q0, representing the core electrode and coating or tissue encapsulation surface 
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capacitance coefficients respectively. Their behavior compared to the same parameters modeled 
from uncoated electrode data is shown in figures 4.8a and b. The CPE phase angle parameter of 
CCPE (β) also demonstrated dynamic change in the coated electrodes but remained at consistent 
elevated values in uncoated electrodes, as shown in figure 4.8c, while the CPE parameter of Q0 
(α) maintained a high value of between 0.85 and 1 for the duration of the experiment for both 
coated and uncoated electrodes. Pore fluid transport resistance RL and conducting polymer 
charge transfer resistance R0 of coated electrodes demonstrated a small degree of variation over 
time that did not correlate with electrode impedance modulus. The solution resistance RSER was 
found to be inconsequentially small compared to other elements and did not contribute 
substantially to quality of fits when varied manually. 
 
 
Figure 4.8: Fitted model parameters. Average fitted values of modeling parameters CCPE (a), QL (b), and β 
(c). QL was not fitted for days 0-2 for uncoated probes due to use of model B. N varied between sessions 
due to measurement exclusion due to noise or artifact. Data presented as mean ± SD. *: p<0.01. 
 
 
Nyquist plots collected from dex/MWCNT/PEDOT electrodes in PBS before 
implantation reveal the characteristic bimodal frequency response typically observed in 
conducting-polymer-coated electrodes, with low frequency behavior dominated by metal 
interface parameters CCPE, RCT, and β, and high frequency behavior characterized by an 
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encapsulation element modeled using ZD. This is contrasted against Nyquist plots of uncoated 
electrodes in PBS, which in the measured frequency range (10 Hz to 32 kHz) demonstrate nearly 
linear constant-phase behavior characterized by CCPE, RCT, and β. The reduction in 1 kHz 
impedance between coated and uncoated probes in vitro most strongly correlates with CCPE, 
suggesting that the principal benefit of the coating is that of greatly increasing the effective 
surface area of the interfacial double-layer capacitance. However, the physical presence of the 
coating also seems to contribute a diffusion barrier to the interface which is most apparent in the 
high frequency regime. It should be noted that within the frequency range measured, the ability 
of fitting techniques to distinguish between RCT and β is limited, particularly in vivo where 
substantial low frequency noise is often encountered during impedance measurement. This is 
particularly true when RCT is very large, as within the arc of visible data points the data will 
appear essentially linear. 
The gradual increase of average in vivo 1 kHz impedance of uncoated electrodes is 
typically characterized by subtle changes in metal interface parameters RCT and β which 
dominate low-frequency behavior, as well as with a gradually emerging high-frequency diffusion 
barrier and encapsulation element modeled using the diffusion element ZD. These changes 
coincide with known physiological events thought to play a role in evolving electrode in vivo 
impedance, with RCT and β representing changes to electrode surface properties due to protein 
adsorption, which takes place immediately upon implantation, and ZD representing the growing 
boundary effect of local tissue changes including inflammation, microglial encapsulation, and 
edema13,40,97. Chronic in vivo studies using uncoated microelectrodes have shown that during 
chronic implant durations the 1 kHz impedance tends to peak at 9-15 days and then reduces to an 
intermediate magnitude where it typically remains at a fluctuating plateau for the experiment 
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duration. This is thought to correspond with the reduction of initial acute inflammation and tissue 
swelling, and the transformation of the interface to a stable chronic inflammatory state21,203. 
Extended chronic impedance behavior was not observable in our data, as we elected to end the 
experiment after 11 days of implantation in order to best observe the impact of the release 
stimulation on acute inflammation using tissue histology. 
In contrast to the behavior of uncoated electrodes, the dex/MWCNT/PEDOT electrodes 
typically demonstrated an initial low-impedance period followed several days later by a rapid 
increase consistent between all coated electrodes. During the initial 3-4 day period post-
implantation the coated electrodes exhibited 1 kHz impedances comparable with pre-
implantation values, with day 1 and 2 values being additionally depressed from values measured 
on day 0. Fitted model parameters CCPE and QL correlate with this depression when averaged, 
suggesting that the coating required a one day “maturation” period to achieve its full surface area 
capacitance benefit. This is possibly due to the time required for electrolyte to fully penetrate the 
pores of the coating, or for the fluid and tissue around the probes to stabilize post-implantation. 
Between day 3 and day 5 post-implantation, the average 1 kHz impedance of coated probes 
increased substantially to the point of equivalence with that of uncoated probes. Nyquist plots 
reveal that this increase is distinctive from the increase observed in uncoated probes, and appears 
principally due to large decreases in parameters CCPE and QL which allowed the encapsulation 
element ZD to dominate greater and greater portions of the measured frequency range. These 
modeling results suggest that beginning at day 3-5, the surface area enhancing benefit of the 
coating was sharply reduced and that a barrier composed of some combination of the coating and 
inflammatory tissue elements began to dominate electrode impedance behavior by way of 
reducing the exposed surface area and thus the capacitance of the conducting polymer. This 
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hypothesis is supported by explant SEM imaging which revealed the presence of a dense 
membranous substance enveloping and interpenetrating the coating pores of all coated 
electrodes. Due to explant preparation for imaging, this substance was compromised before 
identification could be performed, but it is speculated to be a combination of fibroblasts, dense 
ECM, and glia. Despite this chronic impedance behavior, the recording performance of the 
coated electrodes did not appear to be detrimentally affected and histology did not reveal an 
atypical degree of tissue inflammation, suggesting that the encapsulation element is limited to the 
area immediately surrounding and within the coating. Another possible mechanism behind the 
observed behavior is the possible partial delamination of the coating from the electrode metal, 
which would detract from the coating surface area benefit to the electrode while generating a 
large ionic barrier in the form of the detached coating. 
It should be noted that we employed the transmission-line linear diffusion element ZD to 
model both the encapsulation component of the conducting polymer coating as well as the ionic 
diffusion barrier of tissue inflammatory response. ZD has been used to model each of these 
elements separately in other studies205,220,250. We speculate that in most circumstances it is 
unlikely that the impedance contribution of each can be confidently differentiated using 
measurement and circuit modeling alone, particularly if both coating and tissue encapsulation 
exhibit similar time constants. 
 
4.3.3   In Vitro Electrode Impedance Fitting 
 
To better understand the impedance behavior observed in vivo, identically coated electrodes were 
situated within a sealed chamber and chronically immersed in PBS while being subjected to the 
same stimulation protocol applied to the implanted FMAs. This setup serves to remove the 
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contribution of inflammatory tissue response and isolate the impact of release stimulation on the 
impedance characteristics of the coating. Half of the electrodes were subjected to the daily 
impedance measurement-CV stimulation-impedance measurement applied to the in vivo arrays, 
while half of the electrodes were only subjected to daily impedance measurement without 
stimulation. Average measured 1 kHz impedances for each group are shown in figure 4.9a, 
which bears a striking resemblance to the chronic behavior observed from coated electrodes in 
vivo in figure 3.2b. Upon closer examination of the data, the dynamic impedance changes were 
mostly due to the contribution of three of the five stimulated electrodes in particular, while the 
remaining two exhibited very consistent impedances over the duration of the experiment. To 
better evaluate the difference between these consistent (“good”) and inconsistent (“poor”)-
performing stimulated electrodes, for the remainder of the evaluation all electrodes were grouped 
by performance: Non-stimulated (N=5), Stimulated “Good” (N=2), and Stimulated “Poor” 
(N=3). The average 1 kHz impedances for each of these three groups are shown in figure 4.9b. 
 
 
Figure 4.9: Electrode impedances during in vitro measurement. a) Average values of all non-stimulated 
and stimulated electrodes. b) Average values with stimulated electrodes split into two groups: 
consistent “good” and inconsistent “poor” impedance performance. Data presented as mean ± SD. 
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 Figure 4.9a and b reveal that a number of the stimulated coated electrodes exhibit a trend 
of increasing 1 kHz impedance after four days of stimulation, while all of the non-stimulated and 
the remaining stimulated electrodes exhibited very consistent impedance values over the entire 
course of the experiment. By day 11, average 1 kHz impedance of the “poorly performing” 
electrodes approaches the average impedance value of the electrodes before coating (475±162 
kΩ), suggesting that the electrochemical benefits of the coating were being steadily extinguished. 
It should be noted that impedance data from day 8 for the stimulated electrodes were lost due to 
potentiostat technicalities. 
 While the chronic 1 kHz impedance performance of the stimulated electrodes in PBS 
trended in a manner similar to the performance of those implanted in vivo, a more in-depth 
evaluation revealed that the mechanisms behind these performance changes may possess 
important differences. Figure 4.10 presents a number of representative Nyquist plots from non-
stimulated and “poorly” performing stimulated electrodes at different days of PBS immersion. 
These plots may be compared against those in figure 4.7 above. In particular, figures 4.7f and 
4.10f, which represent points of elevated impedance of coated, daily-stimulated electrodes in 
vivo and in PBS in vitro respectively reveal very different patterns of frequency response. While 
the in vivo coated stimulated interface is characterized by a high-frequency encapsulation 
element that increases in magnitude as evident in figures 4.7d-f, the interface in PBS is 
characterized by a diminishment of the high frequency encapsulation element and a gradual 
straightening and lengthening of the plotted response curve. This behavior suggests that while 
the impedance increase of the coated stimulated electrodes in vivo is driven by the development 
of some type of resistive encapsulation around the electrode, the impedance increase in PBS is 
instead a consequence of the gradual loss of electrochemical benefits of the coating as the probe 
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approaches the performance of an uncoated electrode. It is quite possible that this coating loss is 
also occurring in vivo but is being masked from observation by the encapsulation element having 
a dominating influence on electrode frequency response. 
 
 
Figure 4.10: Nyquist plots of in vitro data. a-c) Plots collected from a single coated, non-stimulated 
electrode at three representative days. d-f) Plots collected from a single “poorly performing” coated, 
daily stimulated electrode on the same days. 
 
 
 To better evaluate the interfacial characteristics of the electrodes at different time points 
in vitro, each set of data was examined using equivalent circuit analysis. Data were fit to the 
same model used for in vivo data fitting, model A (Fig. 4.6a). Average values for key fitted 
parameters are shown in figure 4.11, including CCPE (the capacity coefficient of the metal 
interface), and α (the CPE parameter of CCPE, which represents the “idealness” of the capacitor). 
For the purposes of this fitting procedure, the metal interface charge transfer resistance RCT was 
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assumed to be infinite, while the encapsulation element parameters Q1, β, R0, and R1 were not 
considered as the encapsulation element was not observed to exist within data recorded from 
“poorly performing” stimulated electrodes beyond the first few days of stimulation. When 
evaluating fitted parameters, one of the electrodes from the non-stimulated group was removed 
from consideration as it exhibited behavior which deviated from the other four by over an order 
of magnitude. This electrode also exhibited 1 kHz impedance modulus over an order of 
magnitude under the average of the others, possibly indicating an insulation failure. 
 
 
Figure 4.11: Model parameters from fitted in vitro data. a) CCPE, The capacity coefficient of the metal 
interface. b) β, the CPE parameter of CCPE. Data presented as mean ± SD. 
 
 
 In addition to the rapid disappearance of the encapsulation element, fitted parameters of 
the “poorly performing” stimulated electrodes reveal that their capacitance exhibited a steadily 
decreasing trend on average compared to that of the non-stimulated electrodes (though the 
variances were large, reflecting the range of initial impedances of the electrodes pre-coating). 
Additionally, the interfacial CPE parameter α of the “poorly performing” electrodes was seen to 
steadily decrease from a near-ideal value of ~0.98 down to a value of ~0.85, which approaches 
the average α of the bare pre-coated electrodes, 0.83±0.10. Together, the fitted parameters 
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suggest that the “poorly performing” stimulated electrodes suffered a gradual coating failure, 
possibly through a delamination mechanism which steadily removed a portion of the impedance 
benefit of the coating with each passing day of stimulation. As the phenomenon was only 
observed in three out of the five stimulated electrodes, it may be that the failed electrodes 
suffered initial coating defects that made them particularly vulnerable to the mechanical stress 
produced by coating actuation during the CV stimulation process. 
 
 
4.4   CONCLUSION 
 
We demonstrated the utility of the Bisquert equivalent circuit model in evaluating the core 
mechanisms behind the impedance changes exhibited by coated and uncoated electrodes in vitro 
and in vivo. The fitting results were consistent between probes and animals, and suggest the 
occurrence of a coating failure between 3 and 5 days post-implantation, due either to partial 
coating delamination from the metal surface, some loss in coating conductivity, or the 
development of a dense sheath of reactive tissue that acted to reduce the effective surface area of 
the coating. In vitro trials revealed that the coated electrodes may be vulnerable to some type of 
coating failure following daily chronic stimulation. However, the nature of this failure appears 
distinctive between in vivo and in vitro conditions. Further work will need to be performed to 
determine more of the true nature of this coating failure, and to evaluate possible solutions.  
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5.0   CONCLUSION 
 
 
 
5.1   SUMMARY OF RESULTS 
This dissertation describes the biological consequences of chronic cortical probe implantation, 
and the emerging technological approaches to countering these consequences with the goal of 
accelerating progress toward clinical translation. Each study takes a multi-disciplinary approach 
toward the better understanding of the device/tissue interface, and together combine 
biochemistry, electrochemistry, materials science, and neural engineering to develop new tools 
and insights into the problem of long term recording failure. These insights will contribute to the 
scientific understanding of probe interfacial stability, and inform future engineering approaches 
and designs. 
 In chapter 2, we discussed the development of a model for studying the impact and 
benefit of chondroitinase ABC treatment to intracortical recording electrodes to observe whether 
the beneficial outcomes observed within spinal injury studies could be translated to indwelling 
cortical probes. Microinjector design, implantation and injection techniques, and tissue 
preparation and histology methods were studied and optimized to achieve the most consistent 
performance and clear perspective of inflammatory response. Chondroitinase ABC 
microinjection was found to eliminate CSPG around the implant immediately after injection as 
well as significantly attenuate serum proteins, likely due to release of those serum proteins from 
ECM entrapment. However, a pilot study performed featuring the implantation of 
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electrode/cannula hybrid implants indicated no clear chronic impedance-changing effects of 
chondroitinase injection. In summary, the work demonstrated the feasibility of the method and 
the efficacy of microinjected chondroitinase in eliminating CSPG around an implanted probe. 
However, the study also revealed a number of challenges to technique translation, including the 
disturbance of local tissue due to the pressures of obdurator placement and removal, and the 
abundance of exuded serum protein which can bind to anti-mouse Ig secondary antibodies and 
complicate imaging. If these challenges are surmounted, this treatment method will serve as a 
powerful means to better understand the role of CSPGs in chronic neural degeneration and 
electrode performance loss, and could substantially inform future electrode development. 
 Chapter 3 discusses the development and evaluation of a novel conducting polymer-
based drug release coating composition in vitro and in vivo, and provides one of the first 
accounts of the in vivo release of a drug dopant from a conducting polymer coating. PEDOT was 
co-doped with dexamethasone and MWCNTs, which were added to increase the structural 
resilience, adhesion, and effective surface area of the coating to improve stability and drug 
release yield. A stimulus protocol was designed with parameters optimized to achieve a degree 
of release while minimizing tissue and electrode damage, and the protocol was tested in vitro to 
quantify release and observe coating stability. In general, coated and uncoated probes performed 
similarly with statistically identical recording performance and inflammatory response, with the 
inflammatory response was observed to be comparable to that evoked by similar probes over 
similar time periods in other studies. These observations confirmed the safety of the release 
stimulus, the biocompatibility of the coating, and the ability of the coated probes to record neural 
activity. With further optimization and chronic testing, this technology could provide a powerful 
tool for neurophysiological research and next-generation electrode design. 
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 In chapter 4, we discussed the use of equivalent circuit modeling to investigate the 
physical and physiological basis of the loss of impedance benefit exhibited by the coated probes. 
A variety of simple interfacial circuit models were adapted and applied to the data, yielding 
ambiguous results. In the end, we adopted a more sophisticated impedance model described by 
Bisquert et al.248 which demonstrated good fitting and consistent parameter dynamics. Fitting 
indicated that impedance behavior of uncoated probes was dominated by changes to electrode 
surface characteristics as well as the development of a tissue encapsulation element at later time 
points, while coated probes exhibited a large surface area benefit at early time points which 
subsequently diminished, at which point impedance was dominated by a large encapsulating 
barrier. The model thus suggests that this loss is due to some interference of coating function, 
either through the obstruction of the coating surface or the delamination of the coating from the 
metal surface, or some combination of both. From a broader perspective, the study demonstrated 
the application of sophisticated modeling techniques in extracting more profound insights from 
impedance data. Despite impedance measurement being a common element of performance 
evaluation, most studies do not venture beyond simple 1 kHz impedance reporting. However, as 
this study demonstrates, probes may exhibit identical 1 kHz impedance but substantially 
different phase features and interfacial characteristics. Circuit modeling provides a more 
comprehensive method of observing subtle changes to electrode performance. 
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5.2   FUTURE DIRECTIONS 
 
5.2.1   Chondroitinase ABC 
 
The use of chondroitinase ABC in the treatment of spinal injury has shown substantial 
promise125, both through direct application of the enzyme to scar tissue as well as the injection of 
enzyme within brain stem nuclei and spinal tissue upstream from the lesion. While the removal 
of CSPGs and their neuro-inhibitory influence from glial encapsulation around an implanted 
probe may promote neuron survival and sprouting, a number of challenges remain to be 
overcome for the method to become chronically feasible and practical. Physiologically, glial scar 
CSPGs likely serve as only a small component of the neuro-inhibitory environment of the tissue 
inflammatory response, which includes many other factors that would not be affected by the 
enzyme such as myelin inhibition, oxidative stress, probe micromotion, pro-inflammatory 
cytokines, and others. As the prevalence of each of these factors would depend largely on the 
design, implantation method, and inflammatory response of each individual probe, the 
effectiveness of chondroitinase therapy may not translate universally to all implants. This is 
particularly relevant in light of the observation that CSPG expression in scar tissue peaks 
relatively soon after implantation, and diminishes to baseline by the early stages of the chronic 
inflammatory response127,141, and well before the 8-16 week time point when chronic neuronal 
degeneration is generally observed to accelerate9. 
To study the prevalence of CSPG-mediated inhibitory signaling around probes at these 
later time periods, an important next step would be to evaluate the effects of CSPG digestion at 
those time points around actual implanted electrodes, which would allow a combination of 
impedance monitoring, neurophysiological recording, and histological examination. Such work 
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could be carried out using a combined electrode array/cannula hybrid, such as that pictured in 
figure 5.1. Effective chronic delivery of chondroitinase ABC is another challenge. Current 
integrated microfluidics systems do not feature the chronic reliability necessary for consistent 
results, due to crushing and clogging of pores. Large cannulae such as the type used in this work 
are more mechanically reliable but much more invasive, complicating implantation and long 
term tissue stability. The adoption of a lentiviral vector for chondroitinase production within 
target tissue could be an intriguing alternative approach251. 
 
 
Figure 5.1: Illustration of a proposed cannula/multielectrode array implant. 
 
5.2.2   MWCNT/PEDOT Drug Release Coatings 
 
The concept of the electrically-stimulated drug release coating is advantageous in that it allows 
for the release of agent at precisely controlled time points without requiring a bulky and 
unreliable fluidics system. The coatings are easily incorporated onto the recording surfaces of 
most conventional electrode varieties using simple electrochemistry. This on-demand drug 
release mechanism could potentially benefit many applications including closed-loop systems 
designed to release targeted drugs on detecting specific conditions or biomolecules, or the 
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monitoring of neural activity at a very fine temporal resolution after neuromodulatory drug 
release. While this study demonstrated the safety and short-term biocompatibility of a model 
release coating, substantial optimization may still be performed in terms of stimulus design, 
coating morphology and composition, and drug selection. Also, the tissue reactivity and 
neurotoxicity of the coating at much longer implant durations will need to be assessed. 
 The dynamic impedance changes observed in coated electrodes during this study and 
published reports of other similar coatings203,204,206 are theorized to be the result of either 
physiological or physical changes to the metal, coating, and tissue interfaces resulting in a large 
reduction of effective interface surface area. As discussed, these changes could be the result of 
combinations of several phenomena, such as probe encapsulation by a restrictive barrier of 
inflammatory tissue and membranous extracellular material, or physical changes to the coating 
such as swelling or detachment from the metal substrate. To better understand the root of these 
early in vivo impedance changes, in vitro experiments may be designed which isolate specific 
conditions, including electrolyte ionic and protein composition, coating composition and 
deposition method, release stimulus, and substrate metal preparation. While the impedance 
change observed in this study did not coincide with a degradation of the charge storage capacity 
of the electrodes nor a decrease in their recording performance compared to uncoated electrodes, 
at least within the implantation duration studied, further study should be performed to evaluate 
its root cause, as an improved understanding of the changes to conducting polymer coating 
impedance in vivo could lead to improved methodology and design in the future. 
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5.3   CONCLUDING REMARKS 
 
Despite the progress achieved in all aspects of neural prostheses over the past fifty years, 
widespread clinical and commercial translation has been limited beyond a handful of key 
devices. Particularly in the field of brain-computer interface, nearly every element has seen 
profound technical and scientific advancement, from improved neural decoding methods to 
increasingly sophisticated robotic devices and communication systems. Despite this progress, a 
key obstacle to clinical translation remains the chronic unreliability of the cortical prostheses that 
serve as the principal point of contact between tissue and hardware. Unless means are found to 
effectively and reliably expand the functional lifetime of these devices to decades instead of 
months and years, their clinical and commercial application will remain untenable. Equally 
important is that these solutions be practical, mass producible, and not subject to excessive 
regulatory hurdles. As brain-computer interface technology has the potential to drastically 
improve the lifestyle, independence, and occupational wellbeing of millions of disabled 
individuals worldwide, the need for working solutions to this problem remains very relevant. 
 The past two decades of electrode development and research have revealed much of the 
mechanisms behind chronic implant failure, and with this understanding has come an evolution 
in perspective. It is now understood that the tissue-electrode interface is mediated by a 
profoundly dynamic and multi-faceted interplay between many diverse elements, signaling 
pathways, inflammatory processes, and biological, chemical, and mechanical stressors that 
combine to dictate the survival of local neurons. In many ways the interface may be represented 
as a delicate balance of pro-inflammatory and anti-inflammatory factors, overseen by reactive 
and regulatory cellular players. In light of this complexity, it is unlikely that a single “magic 
bullet” approach to electrode development will yield the multiple-decade degree of reliability 
119 
 
necessary for widespread clinical translation. Eventual practical solutions will likely require a 
combination of multi-disciplinary scientific inquiry, advancement in fabrication techniques, 
materials development, and even regulatory reform. 
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